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Abstract 
Multidrug-resistant Mycobacterium tuberculosis (MDR-TB) is a leading cause of 
morbidity and mortality in the Philippines. The purpose of this study was to gain 
knowledge about the relationship between potential risk factors and MDR-TB. Risk 
factors (the independent variables) for MDR-TB (the dependent variable) include 
previous TB treatment, infection with HIV, exposure to patients with drug-susceptible 
TB/MDR-TB, delays in diagnosis and treatment, employment status, smoking, 
imprisonment, alcohol abuse, and poor compliance with TB treatment regimens. The 
study was based on the epidemiological approach to causal inference work. A case-
control study design was used wherein a quantitative method was applied in data analysis 
to assess the strength of the pre-identified possible risk factor(s) association to MDR-TB 
infection.  Data were collected using survey questionnaires that were administered to 
patients (N = 172) from health centers in Leyte, San Mateo Rizal, and San Lazaro. 
Hypotheses were tested using chi-square analysis, Fisher’s exact test, and an odd ratio. 
Drug-susceptible TB respondents who smoked on a daily basis were 3 times more likely 
(95% CI 1.021-13.341, OR 3.69) to develop an MDR-TB infection than were other 
respondents. Respondents who did not comply with the anti-TB treatment regimen were 
9 times more likely (95% CI 2.104-43.059, OR 9.519) to develop an MDR-TB infection 
than other respondents. Health care providers may be able to use study findings to 
develop programs to help drug-susceptible TB patients stop smoking and better comply 
with treatment regimens designed to prevent MDR-TB infection, resulting, potentially, in 
improved public health outcomes for patients.  
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Chapter 1: Introduction to the Study 
Introduction 
Data from the World Health Organization (WHO, 2013a) show that, in 2012, 8.6 
million people globally were infected with tuberculosis (TB), and 1.3 million died of the 
disease. Low- and middle-income countries accounted for 95% of TB deaths (WHO, 
2013a ). More people are dying of the disease with the emergence and proliferation of 
multidrug resistant–tuberculosis bacteria (MDR-TB; WHO, 2013a). 
In 1994, epidemiologists began to monitor drug-resistant TB through WHO’s 
Global Project on Anti-Tuberculosis Drug Resistance Surveillance (Zignol et.al, 2012). 
The project  goal is to assess epidemiological trends of the disease . Data collected and 
analyzed from 127 countries, representing 66% of WHO’s 193 member states, show that 
0-28.9% of TB cases in 2007-2010 were multidrug resistant (Zignol et.al, 2012).  
Enrollment for MDR-TB treatment increased from 2009 to 2012 and is projected to 
further increase by 2015 (see Figure 1). 
In response to the aforementioned findings, public health experts from WHO  
developed a six-point strategy as part of the Global Plan to Stop TB program (WHO, 
2014e). The program’s primary goal is to reduce the global burden of the TB disease by 
2015 (WHO, 2014e). The continued evolution of the TB causing organism strain to be 
antibiotic-resistant could potentially hamper the realization of the Global Plan to Stop TB 
program.  
Several factors have been observed towards a successful treatment of MDR-TB 
infection. Among which are manipulation of the medicine to suit the pediatric patient, 
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some patients are experiencing adverse effect of the medicine since its more toxic, 2 years 
or longer treatment period, daily injections for 6 months and much more expensive (TB 
Alliance, 2013). The longer treatment period can cause side effects which result in poor 
adherence to the treatment regimen (TB Alliance, 2013). As a consequence, the disease 
becomes more difficult and costly to treat each time a patient does not complete his or her 
course of drugs (TB Alliance, 2013). 
 
Figure 1. Drug susceptibility testing coverage among new cases and enrollment in MDR-
TB treatment compared with the targets in the Global Plan to Stop TB, 2011–2015. 
Lines indicate the planned targets; blue squares, the situation in 2009–2012, and orange 
circles, the projected enrollments in 2013–2015. Data on projected enrollments in 2015 
were incomplete. Adapted from Global Tuberculosis Report 2013, page 52. Copyright 
2013by the World Health Organization.  
 
Epidemiologists are concerned about the rise in MDR-TB cases globally and poor 
treatment outcomes. The number of cases reported has tripled between 2007-2010 (WHO, 
2013a). In the 2010 profile, only 48% or so of MDR-TB patients in the cohort had 
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successfully completed treatment (WHO, 2013a). Twenty-eight percent of cases were 
reported as lost to follow-up or had no outcome information (WHO, 2013a; see Figure 2). 
 
 
Figure 2. Global treatment outcomes for patients diagnosed with MDR-TB by WHO, 
2007–2010 cohorts.The total numbers of cases with outcome data are shown beside each 
bar. Adapted from Global Tuberculosis Report 2013, page 57. Copyright 2013 by the 
World Health Organization.  
 
Understanding the risk factors related to the onset of a disease is very critical in 
epidemic prevention. The information obtained in the primary prevention stage is of 
greatest value before the biological onset of illness. The persistent increase in the 
prevalence rate of TB, specifically MDR-TB continues to concern among public health 
practitioners (WHO, 2013a).  
Background 
The high global death rate of TB is due to the presence of the pathogenic causative 
agent Mycobacterium tuberculosis (Mtb), according to researchers (National Institute of 
Allergy and Infectious Diseases [NIAID], 2010). This organism is aerobic and rod-shaped 
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and is present in people with active TB (NIAID, 2010). It can remain dormant for years 
without causing any TB disease symptoms (latent TB) but may eventually become active 
TB (NIAID, 2010). 
Mtb is a very resilient phototrophic organism. The bacterium can adapt to changes 
such as nutrient deprivation, hypoxia, and various exogenous stress conditions throughout 
the course of infection (Cook et al., 2009). The ability of the organism to adapt to 
environmental changes is due to the presence of complex regulatory networks and signals 
that result in temporal gene expression coupled with metabolic and energetic changes 
(Cook et al., 2009). The front line drugs against Mtb infection are isoniazid and 
rifampicin. In cases of MDR-TB infection, however, the bacterium is resistant to isoniazid 
or rifampicin (XDR-TB; WHO, 2014b). When the Mtb bacterium strain is resistant to 
ofloxacin or moxifloxacin or other second-line drugs, the disease is classified as 
extensively drug-resistant tuberculosis (XDR-TB; WHO, 2014b). 
Historical Perspective of TB 
The rich history of tuberculosis dates back to the Stone Age. Around 460 BC, 
Hippocrates called the disease “phthisis.” In modern times, the disease began to be called 
TB (Mackenzie, 2012). It reached the Americas well before Columbus (Mackenzie, 2012). 
After 1600, TB became pandemic and rampaged throughout Europe. TB caused a quarter 
of all deaths by the 1800s (Mackenzie, 2012). DNA analysis of ancient human remains 
obtained from southern Germany (1400–1800 AD), Hungary (600–1700 AD), and Egypt 
(3500–500 BC) revealed high frequencies of TB in all time periods (Zink, 2007).  
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Observers became optimistic about eradicating TB after Robert Koch discovered 
and stained the causal organism in 1882 (NIAID, 2010). This was followed 60 years later 
by the discovery of antibiotics such as streptomycin (1943), isoniazid (1951), 
pyrazinamide and cycloserine (1952), ethionamide(1956), rifampin (1957), and 
ethambutol (1962; Keshavjee & Farmer, 2012). The influx of anti-TB drugs in the market 
has allowed the Mtb organism to adapt in the form of a mutation conferring resistance to it 
(Keshavjee & Farmer, 2012). Thus, epidemiologists monitored anti-TB drug resistance in 
Britain from 1955-1956 and in the United States from 1965-1968 (Keshavjee & Farmer, 
2012). In a 2000-2004 study on Mtb isolates, researchers at Supranational Reference 
Laboratories concluded that the presence of XDR-TB throughout different world regions 
resulted from improper treatment of MDR-TB infection (Shah et al., 2007). The surge in 
MDR-TB infection has been attributed to the increasing resistance of the Mtb organism to 
more than one anti-TB drug (NIAID, 2010).   
Risk Factors for MDR-TB Infection 
Risk factors for the development of MDR-TB infection vary considerably 
depending on the population studied, the reason for the research investigation, and the 
methodology that is applied. In a retrospective study conducted in South West Nigeria 
among pulmonary TB patients with MDR-TB, of the 88 respondents, 55 were resistant to 
at least one antibiotic against Mtb (Daniela & Osmanb, 2011). Resistance was showed to 
be associated with previous history of anti-TB treatment (Daniela & Osmanb, 2011). Data 
revealed that age (OR = 0.86 [95% CI 0.35-2.13]; p = 0.72) and gender (OR = 1.24 [95% 
CI 0.49-3.14]; p = 0.62) were not significantly associated with drug resistance (Daniela & 
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Osmanb, 2011). The authors recommended conducting a national TB drug resistance 
survey specific to South West, Nigeria. The primary aim of the survey was to determine 
the actual burden and risk factors associated with drug resistance to TB (Daniela & 
Osmanb, 2011). 
Previous history of anti-TB treatment was identified as a risk factor for MDR-TB 
infection in a study conducted in the Republic of Georgia. The study was performed from 
July 2005 to May 2006. Previous TB treatment and female gender were identified as risk 
factors of MDR-TB (Lomtadze et al., 2009). The identification of the female gender as an 
MDR-TB risk factor contrasted Daniela and Osmanb’s (2011) findings wherein gender 
was found to be associated to MDR-TB infection. 
In Belarus, a nationwide survey to assess the prevalence of MDR-TB and to 
investigate associated risk factors was conducted from 2010 to 2011. Possible risk factors 
associated with the development of MDR-TB in the study were age, country of birth, TB 
treatment history, the level of education, living conditions, household size, employment 
status, history of imprisonment, alcohol consumption, history of smoking and HIV status 
(Skrahina et al., 2013). Previous TB treatment was found to be the strongest risk factor 
followed by HIV infection, age, history of imprisonment, disability sufficient to prevent 
work, alcohol abuse and smoking (Skrahina et al., 2013).   
Residents living in the old urban areas in Vietnam and is infected with the Beijing 
genotype of Mtb bacteria and is infected with HIV is an  associated risk factors for MDR-
TB infection in a study performed  in Hanoi, Vietnam (Hang et.al. 2013). The researchers 
recommended that careful monitoring be undertaken in areas with a high proportion of the 
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Beijing strain of Mtb and HIV infection to avoid transmission of MDR-TB (Hang et.al. 
2013). However, no clear association between time and geographic location of MDR-TB 
and HIV infection was observed in a metaanalysis study performed by Suchindran, 
Brouwer, and Van Rie (2009). The researchers aimed to determine if HIV infection is a 
risk factor for the MDR-TB infection (Suchindran, Brouwer, and Van Rie (2009). The 
researchers were not able to demonstrate an overall association between MDR-TB and 
HIV or acquired MDR-TB and HIV. These data suggest that HIV infection is associated 
with primary MDR-TB infection. The researchers recommended that other studies be 
conducted to better clarify the relationship between MDR-TB and HIV for all regions of 
the world (Suchindran et. al., 2009).  
Ricks et al. (2012) studied the possible risk factors for the development of MDR- 
TB in Namibia using 117 confirmed cases of MDR-TB. The authors found that risk 
factors associated with the MDR-TB infection were previous hospitalization (OR 1.9, 95% 
CI 1.1–3.5) and contact with a household member with MDR-TB (OR 5.1, 95% CI 2.1–
12.5). These studies show that there is no clear understanding of the risk factors that can 
be associated with MDR-TB infection for it may vary with the socio, cultural, 
demographic and economic conditions prevailing in a country. 
Problem Statement 
In a study completed as part of the Tuberculosis Profile of the Philippines, 2003–
2011, Vianzon, Garfin, Lagos, and Belena (2013) found that 98.9% of the 379,390 
diagnosed cases were pulmonary TB. Further, TB was found to be the sixth leading cause 
of morbidity and mortality in the Philippines. The country has one of the highest numbers 
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of MDR-TB cases and ranks as ninth among the 22 highest TB-burden countries in the 
world (Vianzon, Garfin, Lagos, and Belena, 2013). The emergence of MDR-TB poses a 
serious threat to TB control in developing countries like the Philippines. Besides being 
difficult and expensive to treat, the disease requires a longer period of treatment. The 
Tuberculosis financing profile of the Philippines showed that for 2016 the Philippine 
Department of Health requires $104 million US dollars to operate the TB prevention and 
control program. However, only 21% of the required program cost will be provided by the 
government, 41% international grants, while 38% was unfunded (WHO, 2014a). Further, 
data showed that in the Philippines, 4% of all new TB cases have MDR-TB, and 4.6% of 
all drug-resistant TB cases have XDR-TB (WHO, 2014a).  
I performed a query in the WHO interactive database on the treatment outcomes of 
MDR-TB cases in the Philippines. Figure 3 shows that only 49% of the reported MDR-TB 
cases in 2013 were successfully treated. The figure also shows that 12% died, 1% failed 
treatment, 29% were lost to follow-up, and 8% were not evaluated (WHO, 2014c).  
 
Figure 3. Indicators of diagnosis, notification, and treatment of multidrug-resistant TB, 
by region or country and year Adapted from Diagnosis, Notification and Treatment of 
Rifampicin Resistant TB (MDR-RR TB). From Interactive tuberculosis data visualizations 
World Health Organization.  
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The Philippines Department of Health Tuberculosis Control program approved the 
conduct of the study for there is no study at the present that identify national and 
geographically relevant risk factors for MDR-TB infection in the Philippines. The 
identification of risk factors is critical for TB disease prevention and control, especially in 
the Philippines where public health resources are limited. A person who is identified as 
having an increased risk for diseases can participate in laboratory testing and receive 
treatment prioritization. Early treatment may minimize the detrimental biological, 
psychological and social effects TB disease. 
Nature of the Study 
The study followed the quantitative methodology and used a case-control design. 
The control subjects were selected among patients with drug-susceptible Tuberculosis, and 
the cases were patients with clinically confirmed MDR-TB. The study subjects were 
patients who have been clinically confirmed to be MDR-TB positive. MDR-TB infection 
is the dependent variable of the study wherein the condition already occurred to patients. 
The study l used a semi-structured questionnaire to collect relevant information from 
enrolled participants. 
The quantitative analysis aimed to assess if there is a statistically significant 
relationship between each identified risk factor and the MDR-TB infection. If no 
statistically significant causal relationship is established, the specific risk factors will not 
be considered as direct risk factors (Porta, 2014). 
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Research Questions and Hypotheses 
I sought to answer the following research question: Is there an association between 
MDR-TB infection and the following possible risk factors: previous TB treatment, 
infection with human immunodeficiency virus, exposure to a drug-susceptible TB/MDR-
TB patient, delay in diagnosis and treatment, employment status, smoking, imprisonment, 
alcohol abuse, and compliance with TB treatment regimen. I tested the following 
hypotheses: 
H01: MDR-TB infection is not associated with any of the following possible risk 
factors as determined by the standardized questionnaire: (a) previous TB treatment; (b) 
infection with human immunodeficiency virus; (c) exposure to drug-susceptible TB/MDR-
TB; (d) delayed in diagnosis and treatment; (e) employment status; (f) smoking; (g) 
imprisonment; (h) alcohol abuse and (i) compliance with drug-susceptible TB treatment 
regimen. 
H11: MDR-TB infection is associated with one or more of the following possible 
risk factors as determined by the standardized questionnaire: (a) previous TB treatment; 
(b) infection with Human Immunodeficiency Virus; (c) exposure to drug-susceptible 
TB/MDR-TB; (d) delayed in diagnosis and treatment; (e) employment status; (f) smoking; 
(g) imprisonment; (h) alcohol abuse and (i) compliance with drug-susceptible TB 
treatment regimen. 
Purpose of the Study 
In this study, I assessed the strength of association between identified risk factors 
and the development of the MDR-TB infection in the Philippines. Specifically, I examined 
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whether the following factors are causally associated with MDR-TB infection: (a) 
previous TB treatment, (b) infection with HIV, (c) exposure to a drug-susceptible 
TB/MDR-TB patient, (d) delay in diagnosis and treatment, (e) employment status, (f) 
smoking, (g) imprisonment, (h) alcohol abuse, and (i) compliance with TB treatment 
regimen. Findings may inform efforts by public health professionals and other 
stakeholders in the community to develop effective proactive intervention programs to 
enhance MDR-TB prevention in the Philippines.   
Theoretical Foundation 
This study is anchored in the epidemiological theory of John Snow. He pioneered 
the epidemiological approach to causal inference work with an emphasis on the evaluation 
of preventive, ameliorative, and curative interventions (Fine et al., 2013). The theory 
provided an understanding of the agent, the environment and host as a framework for the 
dynamics of disease transmission. 
Snow’s epidemiological approach started during the outbreak of cholera epidemic 
in London which occurred in 1831–1832 and in 1848–1849 where he used skilled 
reasoning, graphs, and maps to demonstrate the impact of presumed Vibrio cholera 
contaminated water coming from the Broad Street pump. The ideas from the 
epidemiological study of Dr. Snow were published in his book On the Mode of 
Communication of Cholera in 1855 which later was republished as a classic work in 
epidemiology, resulting in lasting recognition of his work (Frerichs, 2009). 
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Definitions 
I have defined the following terms to clarify the terms and variables I used in my 
investigation:  
Acquired resistance: Patients diagnose with TB and taking the anti-tuberculosis 
drug and subsequently acquire resistance (WHO, 2009). 
Cured: Patients that completed the course of anti-tuberculosis treatment and 
laboratory analysis from 5 consecutive sputum cultures demonstrated the absence of the 
Mtb (WHO, 2009). 
Efflux mechanism: The movement of the antibiotic compound out of the cell 
(Machado et al., 2012). 
Efflux pumps inhibitors: Compounds such as thioridazine, chlorpromazine, and 
verapamil that prevents the movement of antibiotic out of the cell (Machado et al., 2012). 
Failed treatment: Patient demonstrated viable Mtb from sputum culture despite the 
12-month antituberculosis therapy (WHO, 2009). 
Multidrug resistant tuberculosis: a condition wherein the strain of Mycobacterium 
tuberculosis is resistant to at least isoniazid and rifampicin (Zignol et al., 2012).   
New case: Patients who denied during direct questioning having had any prior anti-
tuberculosis treatment for up to one month (WHO, 2009).  
Recurrence of TB after treatment: Reinfection of antibiotic resistant Mtb organism 
after treatment from MDR-TB. 
Possible risk factor(s): Variables in the study such as previous TB treatment, 
infection with human immunodeficiency virus, exposure to drug susceptible TB/MDR-TB 
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patient, delay in diagnosis and treatment, demographics (e.g., age and gender), social 
factors (e.g., smoking, imprisonment, unemployment, and alcohol abuse), and recurrence 
of TB after treatment. 
Preferential social mixing: Individual that chooses to associate with others that 
have similar HIV-status and lower average CD4 counts among HIV-seropositive 
individuals (Sergeev, Colijn, Murray, & Cohen, 2012). 
Previously treated:  Patients upon direct questioning admit having been treated for 
TB for 1 month or more (WHO, 2009). 
Primary resistance: Patients who have been previously treated for TB but with 
resistance to one or more anti-tuberculosis drug (WHO, 2009). 
Treatment regimen: Use of MDR-TB - HRZES (H-Isoniazid 300mg, R-Rifampicin 
450mg, Z-Pyrazinamide 1g, E-Ethambutol 800mg, S-Streptpmycin1g) for the first 2 
months, then HRZE for the third month during the intensive phase (Department of Health 
Government of the Philippines, 2003). 
Treatment regimen survey: A type of survey that aims to measure first-line and/or 
second-line drug resistance among a group of selected patients who cannot be considered 
representative of a patient population (WHO, 2009). 
Limitations and Assumptions of the Study 
My interactions with study subjects are one of the limitations of the study. In 
addition due to the archipelagic location of the country, study participants will be limited 
in number and may potentially affect the generalizability of the study results. Study 
participants were obtained from the different Department of Health - National 
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Tuberculosis Control Program treatment centers/hospitals in the country such as San 
Lazaro Hospital and various town health center in the province of Leyte and Rizal.  
Specifically in the towns of San Mateo, Burauen, Dagami, Tanauan, Capoocan, Cariga 
and Barugo. Medical records in the Philippines, especially in some clinics/hospitals 
located outside the capital city, are paper based. Access and completeness of medical 
records provided a limitation in the verification of patient data and consequently in the 
enrollment of cases. Patients from clinics/hospitals where medical record data are not 
complete were considered for enrollment in the study.  This lead to potential selection 
bias, where more participants from urban areas are enrolled in the study.  Another 
limitation of the study was that since data collection was through the use of the 
questionnaires with regards to the respondents past events, recall bias was potentially 
introduced which in most cases items in the questionnaire were left unanswered. The 
researcher requested respondents to answer unanswered questions during the final review 
of the questionnaire. However, in most cases, they refuse to provide an answer which was 
respected by the researcher. The high rate of unanswered questions provided bias to the 
study test results; thus study conclusion cannot be applied to the general population.   
 The assumption of the study is that the laboratory-confirmed study respondents with 
MDR-TB are correct and reliable based on the input from the clinician, including the 
assumption that the study respondents will provide information to the best of their ability.  
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Significance of the Study 
Identifying country specific relevant risk factors of MDR-TB infection that are 
reflective of the socio, cultural, economic, and demographic conditions in the area may 
help prevent the proliferation of the disease. The identification of risk factors can provide 
guidance to health care professionals in the identification of high-risk patients, thus 
increasing the effectiveness of MDR-TB prevention program in the Philippines. It is 
hoped that the results of the study will provide public health officials an additional basis 
for programmatic priority planning and policy decision making in the practice of public 
health. Also, the study can perhaps aid public health practitioners to identify the risk 
differences which can help prioritize resource allocation for the surveillance, control, and 
prevention of MDR-TB. The data that were generated from this study may have a 
potential impact on public health educators and help them educate the general public on 
the modifiable risk factor(s) to prevent if not decrease MDR-TB infection. This study 
hopes to fill in the gap in the literature for no studies have been done on MDR-TB risk 
factors in the Philippines. 
As shown in the graphs below, the incidence rate of TB in the Philippines continue 
to decline from the year 2000 to 2014 and with a success treatment rate of 49%. (Figure 
4). 
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Figure 4. Incidence rate of TB in the Philippines from the year 2000 to 2014 
Adopted from: Tuberculosis Country Profiles (WHO, 2014a). 
 
The identification of risk factors for MDR-TB infection will lead into early 
treatment prioritization and prevent the proliferation of TB disease in the community. In a 
collaborative study by Bishai, Bishai and Bishai (2010), the researchers concluded that in 
populations with low prevalence of drug-susceptible TB, a greater proportion of MDR-TB 
case detection accompanied with compliance with directly observed treatment, short-
course (DOTS) is crucial to prevent TB epidemic. The emergence of a new Mtb strains 
and MDR-TB infection development could trigger an increase in TB prevalence rate in a 
population that lost herd immunity. The study was performed through a computer 
simulation of MDR-TB epidemics (Bishai et al., 2010). DOTS were developed by WHO, 
as the most cost-effective strategy to stop the spread of TB. The treatment program is 
based on five elements such as collaborative sustained effort from the government, case 
detection, standardized treatment, regular, uninterrupted drug supply and a standardized 
recording and reporting system for assessment of treatment result (World Health 
Organization, 2014b). 
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Importance for Social Change 
The result of the study hopes to benefit the members of the community for it can 
be used by public health practitioners as a basis in educating the population on risk factors 
associated with the probability of MDR-TB infection that is relevant to the geographic 
location. Geographically relevant risk factors may be significant for it may allow members 
of the community to easily recognize and modify the situation so as to lessen the risk of 
disease infection and ultimately reduce morbidity due to TB and MDR-TB. 
The Philippines is considered a developing country where there are limited 
resources. The reduction in MDR-TB transmission would result in reduced health care 
costs as a consequence of decreased hospitalization admission of patients with MDR-TB. 
Those limited resources can then be channeled to augment other needed health care 
services for the population. Also, a decrease in MDR-TB transmission will lead to a 
reduction in the bacterial reservoir within the community at large. Because the treatment 
of the MDR-TB infection is expensive, knowledge of the risk factors associated with the 
infection may prevent the disease occurrence in a family member and avert the burden of 
its associated cost. 
Health care providers will be able to prioritize diagnosis and treatment based on 
risk factors knowledge which can save time, financial resources and most importantly  
prevent further damage to patient's organ due to early detection and most effective  
treatment. Another social impact of the study will be that it may help bring equity to the 
underserved group especially that in most cases patients with tuberculosis belongs to   
economically deprived segments of society. 
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Summary 
The Philippines MDR-TB infection ranks as ninth among the 22 highest TB-
burden countries in the world (Vianzon, Garfin, Lagos, and Belena, 2013). With limited 
resources identifying the probable risk factors associated with MDR-TB infection needed 
for patient early treatment prioritization and decrease the proliferation of the disease in the 
community.  The purpose of this study is to assessed the strength of association between 
identified risk factors and the development of the MDR-TB infection in the Philippines. 
Specifically, I examined whether the following factors are causally associated with MDR-
TB infection: (a) previous TB treatment, (b) infection with HIV, (c) exposure to a drug-
susceptible TB/MDR-TB patient, (d) delay in diagnosis and treatment, (e) employment 
status, (f) smoking, (g) imprisonment, (h) alcohol abuse, and (i) compliance with TB 
treatment regimen. I conducted survey questionaire as primary instrument in obtaining 
data from the study participants.  
Chapter 2 of this research include the literature on TB pathogen MDR-TB, 
characteristics, modes of transmission, pathogenesis of the bacterium; the organism’s 
evolution from antibiotic susceptible to multidrug resistant, mechanism for drug 
resistance,morbidity, mortality, and health cost are described in addition to clinical 
presentation, signs, and symptoms to better understand the health impact of MDR-TB 
infection. In addition, chapter 2 also provided MDR-TB geographic distribution, 
manifestation, drug resistance, prevention, and control from published epidemiological 
studies and the state of TB and MDR-TB epidemiology in the Philippines. Chapter 3 is an 
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explination of the methods used to gather and interpret the data. Chapter 4 is a report of 
the data and Chapter 5 is the interpretation of those data. 
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Chapter 2: Literature Review 
Introduction 
The Philippines is a developing country and has one of the highest numbers of 
MDR-TB cases and ranks as ninth among the 22 highest TB-burden countries in the world 
(Vianzon, Garfin, Lagos, and Belena, 2013). The emergence of MDR-TB infection poses 
a serious threat to TB control program of the Philippines government. MDR-TB infection 
requires a longer period of treatment, and a result could consume the resources of the TB 
control program. The study assessed the strength of association between identified risk 
factors and the development of the MDR-TB infection in the Philippines. Specifically, I 
examined whether the following factors are causally associated with MDR-TB infection: 
(a) previous TB treatment, (b) infection with HIV, (c) exposure to a drug-susceptible 
TB/MDR-TB patient, (d) delay in diagnosis and treatment, (e) employment status, (f) 
smoking, (g) imprisonment, (h) alcohol abuse, and (i) compliance with TB treatment 
regimen. 
In this chapter, I provided a brief description and background of the TB pathogen 
MDR-TB. The discussion includes the characteristics, modes of transmission, and 
pathogenesis of the bacterium; the organism’s evolution from antibiotic susceptible to 
multidrug resistant; and the mechanism involve for drug resistance. Morbidity, mortality, 
and health cost are described in addition to clinical presentation, signs, and symptoms to 
better understand the health impact of MDR-TB infection. I discussed current research 
studies on risk factors of MDR-TB infection which served as background of the study 
hypothesis.  
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A discussion of MDR-TB geographic distribution, manifestation, drug resistance, 
prevention, and control from published epidemiological studies are also presented. These 
studies also provide the framework for my methodology. The section on the state of TB 
and MDR-TB epidemiology in the Philippines was also discussed.   
Literature Search Strategy 
I used PubMed and Academic Search Premier databases to identify relevant 
published research studies. Research from WHO and the journals New England Journal of 
Medicine, Emerging Infectious Diseases, Clinical Infectious Disease, and Journal of 
Infectious Diseases were used in the review of related literature. The research terms used 
were multidrug resistance tuberculosis, Mycobacterium tuberculosis (Mtb), antibiotic 
resistance, TB in the Philippines, and TB risk factors. Published studies from 2009 to 2014 
were reviewed.   The basis for the selection of published literature review inclusion are 
those that discussed  MDR-TB, tuberculosis, mycobacterium tuberculosis (Mtb), antibiotic 
resistance, prevention and control, TB in the Philippines, TB epidemiology, disease 
geographic distribution, prevention, control, clinical presentation, and risk factors 
methodologies.  
Pathogenic Characteristics of Mycobacterium Tuberculosis 
General morphological characteristics of Mtb include being rod-shaped or tubercle 
bacilli, slender, nonmotile, and appearing bent or curved (Gengenbacher & Kaufmann, 
2012; Ahmad, 2011). The organism has an impermeable and thick cell walls or capsule. 
The cell wall is composed of peptidoglycans, polysaccharides, unusual glycolipids, and 
lipids. The lipids are made of a long chain of fatty acids, such as mycolic acid 
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(Gengenbacher & Kaufmann, 2012; Ahmad, 2011). The organism belongs to the 
mycobacterium genus and is known to be an opportunistic pathogen due to its ability to 
survive in various types of environment (Cook et al., 2009).  
Gengenbacher and Kaufmann (2012) found out that the ability of the Mtb 
organism to become dormant in a  nonreplicating state is due to low metabolic activity. 
Dormancy in the nonreplicating state allows phenotypic drug resistance of Mtb. These 
findings above were corroborated by Bret, Demetriadou, and Zahrt (2011), who found that 
the Mtb organism adapts to changes in the granulomatous lesions environment. The 
changes could be due to low-oxygen tension, nutrient depletion, reactive oxygen and 
nitrogen species, altered pH, toxic lipid moieties, and cell wall/cell membrane-perturbing 
agents. The adaptation is made possible through transcriptional reprogramming. In 
transcriptional reprogramming, the original genetic expression that would not allow the 
Mtb organism to survive in the unfavorable environmental condition leads to the 
development of a variety of regulatory factors (Bret et al. 2011). Among these factors are 
11 complete two-component signal transduction systems (TCSSs), several orphaned 
response regulators (RRs), and sensor kinases (SKs) (Bret et al. 2011; Forrellad et al. 
2013). Virulence genes develop that contain the code for the virulence factor protein 
molecule which allows the Mtb organism to survive in the form of positive response to the 
host immune reaction (Forrellad et al. 2013).   
An important characteristic of this infectious agent of tuberculosis is that the 
organism does not require specific nutritional substances for normal metabolism and 
reproduction. The ability of the Mtb organism to survive in various types of nutritional 
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substances provides ease of growth, proliferation and infection (Gouzy et al. 2013).  The 
flexible catabolic pathways allow multiple carbon and energy sources utilization from the 
infected person to play a critical part in the mycobacterial physiology and virulence that 
place TB disease as one of the global leading causes of morbidity and mortality (Gouzy et 
al. 2013).  
Furthermore, when bacteria infect the human body, the macrophage (a type of 
white blood cell) engulfs and digests the microbe (phagocytosis) and initiates adaptive 
immunity in conjunction with lymphocytes (Meena & Rajni, 2010). Mtb uses the 
macrophage for its replication through various survival mechanisms, which then allows 
the macrophage to remain available to host the pathogenic organism (Meena and Rajni, 
2010). The survival mechanism could be through inhibition of phagosome harboring the 
Mtb with a lysosome, acidification of the phagosome, protection from oxidative radicals, 
TACO protein on the phagosome, and expression of virulence proteins in the PE-PGRS 
family (Meena & Rajni, 2010). These Mtb survival strategies are comprehensively 
described by Gengenbacher and Kaufmann (2012), who contend that the survival success 
of Mtb is based on three capacities, which are first reprogramming of macrophages after 
primary infection /phagocytosis in order to prevent its own destruction initiating the 
formation of well-organized granulomas, second comprising different immune cells to 
create a confined environment for the host–pathogen standoff; and third the capability to 
shut down its own central metabolism, terminate replication and thereby transit into a 
stage of dormancy rendering itself extremely resistant to host defense and drug treatment 
(Gengenbacher & Kaufmann, 2012, p. 514).  
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Meanwhile, one third of the global human population harbors Mtb in dormant form 
(Guptaa, Kaula, Tsolakib, Kishoreb, & Bhakta, 2011). Considering this figure, public 
health professionals should underscore the importance of addressing the issue on how to 
prevent Mtb infection.  WHO data showed that 1.3 million died from the disease in 2013, 
of which 320,000 were HIV-positive individuals as a result of comorbidity (World Health 
Organization (WHO, 2013a).  
Modes of Transmission of Mycobacterium Tuberculosis 
The mode of transmission for MDR-TB strains is the same to that of drug-
susceptible Mtb organism strains. The primary mode of transmission of Mtb is through 
inhalation of the tubercle bacilli that is present in the microscopic droplets from an active 
TB infected person (Versalovic et al. 2011). The microscopic droplets of 1-5 micron in 
size, once exhaled, easily mix with air circulation until a susceptible person inhales the 
droplet nuclei (Versalovic et al. 2011). The expulsion of the microscopic droplets can also 
potentially occur when an active TB-infected person coughs, sneezes, speaks, sings, or 
laughs (NIAID, 2010a). However, not all persons exposed to microscopic droplets 
containing Mtb bacilli develop tuberculosis. In fact, the risk of developing active TB 
disease is only 10% for a person with a latent infection which is accelerated to 10-15% per 
year to progression for patients with HIV (WHO, 2014d; Versalovic et al., 2011; Ritacco 
et al., 2012).  
Understanding disease transmission is one of the tenets of the science of 
epidemiology. The proliferation of TB in a population can be prevented by understanding 
the mode of transmission which can then be the foundation for the conceptualization and 
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development of appropriate, correct proactive infection control measures. TB bacilli can 
also be transmitted in a workplace as demonstrated in a study by Jonsson, Kan, Berggren 
and Bruchfeld (2013).The researchers applied restriction fragment length polymorphism 
technique to cluster the M. tuberculosis. The isolated organism was from healthcare 
workers who develop TB within ten months after the death of an HIV-positive patient 
with pulmonary tuberculosis. Study results showed that there was a correlation between 
the number of working hours and risk of acquiring tuberculosis infection and disease. 
Jonsson et al., (2013) recommended that healthcare workers should undergo screening for 
latent TB as a baseline reference in case of future contact-tracing after an accidental 
exposure. The aforementioned study exemplifies the occupational transmission modality 
and is also present among dental hygienist. TB infection occurred among dental hygienist 
after working for several months with patients coming from countries in which TB is 
endemic (Merte, Kroll, Collins, and Melnick, 2014). 
Though social interaction has shown to contribute the transmission of Mtb, 
physicochemical environmental parameters likewise play a role in the proliferation of the 
microscopic droplets that contain the Mtb bacilli. The observed cause of the seasonal rise 
of tuberculosis during winter is crowding. This was affirmed by a study performed from 
1993 to 2004 in the Netherlands (n = 4,746) using autocorrelation function plots and 
spectral analysis. The researchers found out that the increased transmission of TB during 
winter time is unlikely to be the only cause of the seasonal peak in TB notifications 
(Soetens, Boshuizen, and Altes, 2013).  
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Whenever human overcrowding occurred due to limited space; the situation is a 
potential, excellent ground for Mtb proliferation especially when an infected person in the 
group coughs. López et.al, (2013) performed a study to evaluate the use of cough-
generated aerosols of M. tuberculosis to predict recent transmission. Multivariable logistic 
regression analysis with cluster adjustment was applied to analyze predictors of new 
infection among patients with pulmonary TB. The respondents of the study underwent a 
standard evaluation and collection of cough aerosol cultures of M. tuberculosis. The study 
data revealed that household contacts of patients with TB who produced high aerosols 
(≥10 CFU) were more likely to have a new infection compared with contacts of TB 
patients with low-aerosol (1-9 CFU). , Patients with a high TB aerosol contact was the 
only predictor of new M. tuberculosis infection in unadjusted and adjusted analyses. The 
importance of identifying the reservoir of TB transmission within the community deserves 
increased focus. This could be done by intensive household contact tracing to attain an 
effective disease transmission reduction (Kompala, Shenoi, and Friedland, 2013). 
In the continental United States, about a fifth of MDR-TB cases can be linked to 
transmission within the country. The disease reservoir is infected person who already 
acquired TB before entry into the country (Moonan et al., 2013).The data from this case 
finding study showed that 20 (22%) of these individuals developed MDR-TB as a result of 
the transmission within the country. The researchers found out that 38 (41%) were deemed 
to have reactivation of disease. However 14 (15%) respondents had a known previous 
episode of tuberculosis outside the USA; five individuals (5%) had documented the 
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treatment of the previous episode, and nine cases (10%) insufficient evidence to 
definitively classify reason for disease transmission (Moonan et al., 2013).   
It is then apparent that there is a need to fully understand the risk factor for 
communicable disease transmission to develop a disease transmission control program 
like those geared for MDR-TB. Such program could be community-based treatment. 
Community-based treatment program offers important advantages over the hospital or 
clinic-based care not only in cost and effectiveness. It allows rapid identification of 
infectious cases especially in drug-resistant cases, followed by effective and fully 
supervised treatment (Nardell and Dharmadhikari, 2010). 
The study by López et al., (2013) suggested that Mtb transmission is better 
predicted in cough aerosols than sputum smear microscopy or culture. Close and frequent 
proximity to TB-infected persons that coughs are an excellent mode of Mtb transmission. 
The finding above is further corroborated in a study by Kopeć et al., (2012). The 
researchers studied 35 family households in Poland using spoligotyping and the 
mycobacterial interspersed repetitive unit-variable-number of tandem repeat (MIRU-
VNTR) typing. Results of the study demonstrated that out of 78 patients, 49 (63%) of the 
infection was attributed to intra-household transmission.  The finding clearly supports the 
study conclusion of López et al., (2013) that household setting is an important reservoir of 
Mtb transmission.   
DRUG-RESISTANT TUBERCULOSIS  
History of drug resistance 
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Tuberculosis has almost threatened the very existence of humanity in the 
biosphere. Since the time, immemorial this white plague has caused the loss of millions of 
lives. The discovery and development of streptomycin in 1944 paved the way for the 
treatment of TB infected person. The treatment was considered as the first world drug trial 
involving randomization of study participants (Keshavjee and Farmer 2012). However, 
resistance to the first anti-tubercular drug became apparent as shown by some patients 
with relapse. Laboratory tests showed that the bacilli from the sputum of that patient were 
resistant to streptomycin due to a mutation in the 16S ribosomal DNA (rrs) and the S12 
ribosomal protein gene (rpsL). The resistance was attributed to the drug mechanism target 
of disrupting the bacterial protein synthesis (Goldberg, Siliciano, and Jacobs, 2012).  
Since then, research on new antitubercular medication has lead to the development 
of isoniazid, pyrazinamide, cycloserine, ethionamide, rifampin, and ethambutol. Drug 
resistance always threatened the effectiveness of the monotherapy due to Mtb selective 
mutation (Keshavjee and Farmer 2012). Antibiotics currently available for TB treatment 
act differently on Mtb. As shown in Figure 5, the synthesis of Mtb cell wall is inhibited by 
isoniazid and ethambutol. Rifampin inhibits the synthesis of RNA and pyrazinamide 
antibiotics prevent the microbial growth by disrupting the plasma membrane and energy 
metabolism (NIAID, 2012b).   
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Figure 5. First-Line Treatment of Tuberculosis for Drug-Sensitive TB. Courtesy 
National Institute of Allergy and Infectious Diseases. Adopted from: NIAID, (2012b). 
 
 
Recognizing the potential for antibiotic resistance, combining anti-TB drugs or 
multiple drug chemotherapy became the standard of treatment specially that drug 
resistance has received increased attention in the early of 1990's since TB became a co-
morbidity of Human immunodeficiency virus- immunodeficiency syndrome ( HIV-
AIDs).A typical example was the study on modeling the dynamic relationship between 
HIV and the risk of drug-resistant tuberculosis by Sergeev, Colijn, Murray, and Cohen 
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(2012). The researchers concluded that the rise in HIV could increase the prevalence of 
MDR-TB in populations due to preferential social mixing among individuals. 
Classification of Drug Resistance 
The emergence of MDR-TB undermines the effort of the World Health Organization 
through the Millennium Development Goals (MDGs) and by the Stop TB Partnership. The 
programs aim to reduce by 50% TB prevalence and death rates towards the end of 2015 
and to eliminate TB as a public health problem by 2050 (WHO, 2014e). The current 
epidemiological standard for MDR-TB classification is provided in the World Health 
Organization Guidelines for surveillance of drug resistance in tuberculosis – 4th ed. The 
treatment regimen survey aims to determine the predominant source and pattern of MDR-
TB. The source of the classification provides a clear definition of patient's registration 
groups by the history of previous treatment. The classifications are a new case, previously 
treated case, primary resistance, acquired resistance, cured and failed (WHO, 2009). 
Mechanism of Drug Resistance 
The mechanism of Mtb drug resistance has been studied using molecular genetics 
approach. Understanding the mechanism involved in drug- resistance is critical in the 
development of new anti-TB medicine besides the fact that the presence of drug resistance 
Mtb compounds the problem of eliminating TB. Mtb drug resistance could be 
intrinsic/natural or acquired. The natural presence of an unusual structure of the mycolic 
acid-containing cell wall allows a low permeability of chemotherapeutic compounds such 
as antibiotics on top of the role of efflux mechanism (Da Silva and Palomino, 2011). This 
was further substantiated by an in vitro induction study that aimed to investigate the 
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mechanism by which resistance towards isoniazid develops and how overexpression of 
efflux pumps favors mutations development in isoniazid targets (Machado et al., 2012). 
The aforementioned study applied a prolonged serial exposure of Mtb strains to the critical 
concentration of isoniazid. The study revealed that susceptible and rifampicin mono-
resistant strains once exposed to this concentration become resistant to isoniazid after 
three weeks, and that resistance observed for the majority of these strains could be reduced 
using efflux pumps inhibitors due to overexpression efflux pump genes. Machado et al., 
(2012) further provided justification that intrinsic or natural resistance, as exemplified by 
the efflux, pumps mechanism allows the maintenance of an isoniazid-resistant population 
in a sub-optimally treated patient. 
The repeated and inappropriate use of antibiotic is a major cause of acquired 
antibiotic resistance. The resistance may also develop as a result of chromosomal 
mutations wherein the number of chromosomes or the bacterial structure is changed or 
through horizontal gene transfer that involves the alteration of the original genetic code 
(Smith, Wolff, & Nguyen, 2013). The chromosomal mutation was examined by 
Georghiou et al., 2012. The researcher made use of published studies to determine Mtb 
mutations association with resistance to Amikacin (AMK), Kanamycin (KAN), 
Capreomycin (CAP) antibiotics. Further, the researchers also characterize the diversity 
and frequency of mutations as well as describe the strength of the association between 
specific mutations and phenotypic resistance in global populations. The researchers found 
out that genes rrs A1401G mutation were present in the majority of AMK, KAN, and CAP 
resistant Mtb strains, but was also found in 7% of CAP susceptible strains (Georghiou et 
32 
 
 
al., 2012). Isoniazid and Rifampicin are the common first line of drug in the treatment of 
tuberculosis. The Mtb genes involved in acquired antibiotic resistance to isoniazid are 
katG, inhA, ndh, and ahpC which function for prodrug activation, drug target, and activity 
modulation and resistance marker respectively. Likewise, rpoB gene reacts on drug target 
and is involved in rifampicin resistance (Smith, Wolff, &Nguyen, 2013) 
Epidemiology of Drug Resistance Tuberculosis 
The MDR-TB infection has spread globally. This was observed since the 
introduction of the first anti-tuberculosis drug streptomycin in 1944.  Microbial culture of 
patients that underwent relapse of the disease showed resistance to the antibiotic 
(Keshavjee, and Farmer, 2012). WHO in 1994 initiated the Global Project on Anti-
Tuberculosis Drug Resistance Surveillance. The program systematically collected and 
analyzed data from 114 countries WHO, 2010a). The 2010 surveillance data of countries 
(see Table 1) that reported first-line anti-TB drug resistance show the highest level of 
resistance is in Europe. A total of 44 countries or 83% reported first-line anti-TB drug 
resistance out of 53 European countries monitored. South-East- Asia where the 
Philippines is located, ranks third with six countries out of 11 (55%) reporting first-line 
anti-TB drug resistance. In this year alone, the global proportion of MDR-TB among new 
TB cases reported ranged from 0-28.3% (WHO, 2010a).   
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Table 1 
 
Number of Countries Reporting Data on Resistance to First-Line Anti-TB drugs by WHO 
Region 
 
Note. Republished from Multidrug and extensively drug-resistant TB (M/XDR-TB) 
          2010 Global Report on Surveillance and Response. Copyright 2010 by the 
          World Health Organization.  
 
The proliferation of this disease especially MDR-TB is of grave concern to public 
health for it transcends borders, thus potentially undermines if not reverses the 
achievement of TB control and eradication led by WHO. Moreover, the treatment of 
MDR-TB is difficult and complex when compared to that of drug-susceptible TB. It takes 
up to two years, involving daily injections of very toxic medicine for six months, and is 
significantly more expensive. The cost associated with MDR-TB treatment imposes a 
significant challenge to the government health care system and especially to vulnerable 
low income families (Tuberculosis Alliance, 2014). Besides the social stigma associated 
with the disease that destroys families, the productivity loss attributable to TB is 4 to 7 
percent of the Gross Domestic Product (Tuberculosis Alliance, 2014).  
It is within this framework that the National Strategy for Combating Antibiotic 
Resistant Bacteria was initiated last September 2014 by the United States Government. 
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The initiative is a bold step to slow the global public health threat of antibiotic-resistant 
bacteria typical of which is MDR-TB. The initiative will be achieved in collaboration with 
the international communities among which is the Trans-Atlantic Taskforce on 
Antimicrobial Resistance and WHO Global Action Plan for Antimicrobial Resistance. The 
first two goals of the plan were to: (1) slow the emergence of resistant bacteria and 
prevent the spread of resistant infections, (2) strengthen National One-Health surveillance 
efforts to combat resistance (U.S. Government – White House, 2014). Antibiotic 
resistance is a threat to public health and the economy. In the United States of the 9,588 
TB cases reported in 2013, it was estimated that 1-2% has MDR-TB. The treatment cost 
per case based on the 2010 dollar value is $134,000(U.S. Government – White House, 
2014). 
Geographical prevalence of MDR-TB transcends country's economic and health 
care system condition. The drug resistant organism could easily be introduced and 
proliferate from one country to another especially now a day that people can easily travel 
because of the modern mode of transportation. The most recent global surveillance data, 
as shown in Figure 6, percent of new MDR-TB cases in some parts of the former Soviet 
Union have reached 18 percent, and in the Philippines, the percent of new cases is at 3 to 
5.9 percent (WHO, 2013a). More than 80% of those who contracted MDR-TB in North 
America and Europe died; today the disease is now common in India and China. 
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Figure 6. Percentage of new TB cases with MDR-TB, 1994-2012. Adapted from: WHO, 
(2013) 
 
MDR-TB affects a person of any age, and one of the most MDR-TB vulnerable 
population groups are children under 15 years of age. The World Health Organization 
drug resistance surveillance data between 1994 and 2011 were analyzed to test the 
association between MDR-TB and age group by Zignol et al. (2013) using odds ratios 
derived by logistic regression. The odd ratio of MDR-TB in children compared to adults 
varies between countries. In Germany, Namibia, South Africa, the UK and the USA, 
children <15 years appear to be at significantly higher risk for MDR-TB. The researchers 
concluded that of the risk of MDR-TB in children and adults are similar in many settings. 
This finding was later supported by a recent study that aimed to quantify the global 
incidence of MDR-TB disease in children (Jenkins et al., 2014). Results of the study data 
after statistical analysis showed that the risk of MDR-TB was nearly identical to children 
and adults since both groups are exposed to the same local risk. In this meta-analysis 
study, the researchers considered 3,403 published research studies, of which only 97 
studies met inclusion criteria. Statistical calculation of the risk estimated around 1,000,000 
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(95% Confidence Interval: 938,000 –1,055,000) children developed TB disease in 2010, 
among whom approximately 32,000 (95% Confidence Interval: 26,000 – 39,000) had 
MDR-TB (Jenkins, et al, 2014). 
RISK FACTORS FOR MDR-TB AND METHODS USED IN THE STUDY  
Identification of risk factors is critical since it serves as the foundation for the 
development of disease prevention and control strategy program. Because of their 
fundamental role, the identified risk factors should be a result of scientifically based 
evidence of causality (Porta, 2014). Health risk factors related to MDR-TB increase the 
chance of getting the disease; nevertheless, it does not imply that the person exposed to 
such identified risk factors will develop the disease. What is significant to know if 
preventive care was received after exposure to the risk factor. Preventive care has 
demonstrated to be very valuable in early disease detection and infection proliferation 
control among the population especially for a transmittable disease like MDR-TB.   
Various risk factors for MDR-TB have been identified depending on the intent of 
the study and respondents geographical location. Risk factors for the MDR-TB infection 
are influenced by sociobehavioural, demographic, and economic condition prevailing in 
the study area coupled with the respondent’s current health condition. In a meta-analysis 
study done by Zhao, Li, Zhang, Wang and Liu (2012), evaluation and analysis of 16 
studies obtained from PubMed and Chinese BioMedical databases was performed. MDR-
TB was significantly associated with poor quality of Directly Observed Treatment Short-
course, poor treatment adherence, previous treatment, poverty, and age. The findings were 
a result of selected published articles that were independently reviewed following certain 
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inclusion criteria, and the data were analyzed using Review Manager Software. In a 
similar study done in the eastern part of China, the case-control study design was utilized 
to determine the risk factors for MDR-TB among previously TB treated patients. Pre-
identified TB patients resistant to at least isoniazid and rifampin were classified as cases, 
and those, who are susceptible to the TB drug, were under the control group. Multivariate 
analysis of data showed that the risk factor associated with MDR-TB is the previous 
treatment of TB (Chen et al., 2013). The treatment course for TB sometimes takes a longer 
period providing a great chance for the patient to comply poorly with the prescribed 
treatment regimen. Liu et al. (2013) conducted a similar study in Northeastern China. One 
of the inclusion criteria in the study was that the sputum collected from the respondent 
should show positive for the presence of Mtb bacteria in addition to being a resident of 
Lianyungang City. Besides the laboratory report, other data were obtained from personal 
information, physical examinations, present illness, TB-related complaints, previous 
medical history, family history and the purified protein derivative test (skin test) result 
(Liu et al.,2013). The data were obtained through interview and review of respondents’ 
medical records (Liu et al., 2013). Using SPSS version 13.0 data were stored and analyzed 
to determine the probable association between selected factors. The odds ratios and 95% 
confidence intervals from an unconditional logistic regression model with P < 0.05 based 
on a two-sided test was applied as the criterion for significance (Liu et al., 2013). The 
researcher found a similar result that previous treatment classified as the first treatment of 
more than eight months and more than three prior episodes of anti-TB treatment was an 
important risk factor for the MDR-TB infection.  
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Van der Wef, Langendam, Huitric and Manissero (2012) performed a meta-
analysis of studies published from the database in MEDLINE and EMBASE on drug 
resistance after inappropriate TB treatment. The study aimed to assess the evidence that 
inappropriately following the prescribed tuberculosis treatment regimen is a risk factor for 
the development of MDR-TB. The researchers found out that there was not enough 
evidence that MDR-TB development is caused by inadequate treatment. One of the studies 
that were reviewed showed a 27 fold increase of developing MDR-TB in patients who 
failed treatment when compared to those patients that observed appropriate treatment 
regimen (Van der Werf et al., 2012). What is significant in studies done by Zhao, et. al., 
(2012) and Chen et al. (2013) was that their results underscore the importance of a high-
quality standard antibiotic treatment and a strict follow-up of patients to ensure adherence 
to the prescribed regimen. This is done to avoid possible mutation or evolution of the 
organism into drug-resistant strain otherwise exposure to TB treatment becomes a risk 
factor for the development of drug-resistant organisms. 
In addition to poor quality of previous TB treatment, gender, and age other 
contributing risk factors for MDR-TB were also ascertained by Rifat et al. (2014). MDR- 
TB patients, who are the subject of the study, were randomly selected from government 
hospitals located in urban and rural areas of Bangladesh. The researchers applied the case-
control study design wherein the drug-susceptible TB patients (N = 750) are in the control 
group while the MDR-TB patients (N = 250) are the cases. All recruited study respondents 
were of confirmed diagnosis for MDR-TB. A face-to-face interview using a structured 
questionnaire, and clinical record reviews were conducted to obtain socio-demographic 
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information to develop the database. The questionnaire was designed to obtain data on 
possible risk factor association on predictors such as the previous history of TB treatment, 
gender, age group, education, occupation, smoking status, substance misuse and presence 
of type-2 diabetes. Data was analyzed using unadjusted and multivariable logistic 
regressions. Results of the study showed similar strong association (Odd Ratio 716.6, 95% 
Confidence Interval 282.1-1820.8) of previous TB treatment history with that conducted 
by Liu et al. (2013). Previous TB treatment history was predominant (98%) among MDR-
TB patient respondents in this study compared to drug-susceptible TB patients (6.4%). 
Other risk factors associated with MDR-TB infections in the following decreasing order of 
association are; age, education, service, business as occupation, service and business as 
occupation and type 2 diabetes (Rifat et al., 2014).  
Type 2 diabetes is not the only identified comorbid illness identified as the risk 
factor associated to MDR-TB but also the presence of Human Immunodeficiency Virus 
(HIV) infection. Skrahina et al. (2013) conducted a survey study in Belarus wherein one 
of the study aim is to ascertain the risk factor for MDR-TB proliferation in the country. 
Respondents of the study were not classified between cases and control. The two sputum 
samples submitted by respondents were subjected to acid-fast direct microscopy 
examination, and the other was cultured to determine drug resistance or susceptibility. 
Proper treatment was provided to the respondents. Structured questionnaire interview was 
applied to gather information on sociobehavioural, treatment history, demographic 
characteristics, education, living and employment conditions, history of imprisonment, use 
of alcohol, smoking and HIV infection (Skrahina et al., 2013). Data analysis generated 
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from the EpiInfo software package version 3.5.1 wherein all the information were stored 
and statistically subjected to Pearson X2 to compare categorical variable. Analyses showed 
that previous treatment history was the number one risk factor for MDR-TB infection. The 
Odds Ratio was 6.1; 95% Confidence Interval: 4.8–7. This was followed by the presence 
of HIV infection with Odds Ratio: 2.2; 95% Confidence Interval: 1.4–3.5 (Skrahina et al., 
2013). The researchers considered the possible risk factor to be associated with the MDR-
TB infection if the P-value is <0.05. Statistical analysis revealed that in Belarus, the risk 
factors for the MDR-TB infection are age < 35 years, history of imprisonment, disability 
sufficient to prevent work, alcohol abuse and smoking (Skrahina et al.,2013).The result of 
the study perhaps indicates that the convergence of HIV and MDR-TB infections is of 
great public health concern. This requires a stronger collaboration between the two disease 
control programs and most importantly acceleration of TB resistance detection and 
improvement to treatment adherence.  
HIV as a risk factor for the MDR-TB infection was found to be similarly 
correlated in a study done in Hanoi, the capital of Viet Nam (Hang et al., 2013). Clinical 
and epidemiological information were collected by the researchers in this study from 506 
newly diagnosed patients with sputum smear- and culture-positive TB. Data were 
subjected to adjusted odds ratio analysis to determine risk factors degree of correlation to 
drug resistance. Interesting in this study was that the researchers aimed to understand the 
risk factor associated with TB drugs (isoniazid, rifampicin streptomycin, and ethambutol) 
resistance and multi-drug resistance from the Mtb. TB drug resistance test was performed 
on isolates cultured from respondent’s sputum. Study result showed that risk factors 
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associated with isoniazid resistance include living in old urban areas, the presence of the 
Beijing genotype, and clustered strains.  Patient with the Beijing genotype strain of Mtb is 
resistant to streptomycin (Adjusted Odds Ratio: 2.10, 95% Confidence Interval; 1.29–
3.40). Moreover, HIV co-infection was found to be associated with rifampicin resistance 
and MDR-TB (Hang et al., 2013). The researchers of the study concluded that Mtb drug-
resistant strains could be avoided based on the result of drug susceptibility, coupled with 
monitoring to ensure treatment prescription adherence. 
The identification of risk factors can also be studied following a descriptive case 
series study design, wherein data are obtained through structured interview and abstraction 
of treatment record from patient (Pant et al., 2009). In this study, the data was gathered 
within eight months period from respondents in a DOTS-Plus clinic at Bhim Hospital, 
Bhairahawa. The study did not have a case-control. However, the authors found out that 
the primary risk factors for MDR-TB are previous TB treatment followed by male sex, 
poverty, migration to India, illiteracy, and smoking (Pant et al., 2009). 
The literature review showed that varying study design and data gathering strategy 
could be applied to determine the risk factor of MDR-TB. Terlikbayeva et al., (2012) 
applied correlational and descriptive analyses to determine the MDR-TB risk factor and its 
temporal and spatial distribution in Kazakhstan. This study considered social, economic 
and environmental factors as possible determinants of drug-susceptible TB and the MDR-
TB infection. Specifically, the researcher analyzed the TB surveillance data from the 
National Institute of Geography (NIG) and the National Tuberculosis Program (NTP). The 
analysis centers on the possible association of MDR-TB infection of alcohol use, 
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vulnerable group, the presence of diabetes, drug use, jail history, migration status, TB 
treatment history, occupation, exposure to TB patient, and if recent mother. The data were 
subjected to descriptive statistical analysis using Microsoft Excel 2010 and SAD 9.2. 
Thou correlation analysis was not applied in this study; the researchers found out that 
most study respondents with the MDR-TB infection had previous contact with the patient 
with drug-susceptible TB or MDR-TB (Terlikbayeva et al., 2012). In addition, the study 
demonstrated that MDR-TB cases increase in Kazakhstan as the prevalence rate of drug-
susceptible TB decrease thereby threaten the gain in the TB control program. 
The proliferation of MDR-TB within the household or community as a result of 
social interaction, behavior, demographic and health conditions has been observed in 
studies. Cohen et al., (2011) using spoligotyping and 24-loci mycobacterial interspersed 
repetitive unit–variable number tandem repeat to classify isolates from 101 households in 
Lima, Peru wherein >1 MDR-TB patient received treatment from 1996–2004. The 
primary purpose of the study was to estimate the frequency of multiple introductions of 
MDR-TB into households. The researcher made use of genetic marker to track Mtb 
organism. Data showed ≥ 10% of households are re-infected with the same MDR-TB 
strain, and 4% are from different MDR-TB strains. Interestingly the proliferation of MDR-
TB in a community could be brought about by migrants who have been exposed to 
resistant Mtb strains, and possibly inadequate TB treatment (Bojorquez et al., 2013). This 
was the findings of Bojorquez et al., (2013) wherein data from Mexico's National TB 
Drug Resistance Survey (2008-2009) was subjected to multivariate analysis. Factors 
associated with MDRTB are previous anti-tuberculosis treatment, Mexico-born TB 
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patients in California and those born elsewhere had greater odds of MDR-TB infection 
compared with patients who were born in the US (Bojorquez et al., 2013). 
CLINICAL PRESENTATION OF TB AND MDR-TB 
There is no difference in the clinical presentation of MDR-TB with that of drug-
susceptible TB. A bad cough that last three weeks or longer, pain in the chest, coughing 
with blood or sputum (phlegm from deep inside the lungs), weakness or fatigue, weight 
loss, no appetite, chills, fever, sweating at night are the general symptoms of the disease 
(CDC, 2012). Other respiratory symptoms may include shortness of breath, chest pains, 
and hemoptysis (WHO, 2010b).   
To rule out the possibility that a patient may be infected, various diagnostic tests 
are available. Some active TB-infected patient' do not exhibit respiratory symptoms thus 
the application of chest x-ray is a valuable tool to identify the presence of pulmonary 
lesions that may indicate the presence of the disease. However, the most definitive means 
of diagnosis are through culture collection from three-morning sputa. Culture collection of 
Mtb bacteria is considered the “gold standard” for TB diagnosis (WHO, 2010b). On the 
other hand, patients with latent TB infection can be tested using tuberculin skin testing as 
indicated by 5 mm induration two to three days after intradermal injection of M. 
tuberculosis antigens (Konstantinos, 2010). Clinical symptoms of TB vary especially 
those with extra-pulmonary TB located in lymph nodes, kidney, bones, and brains making 
it difficult for diagnosis and monitoring treatment progress (Zhang et al., 2011). 
Since symptoms of MDR-TB and drug-susceptible TB are not different this, 
becomes difficult for clinicians to diagnose and prescribe the appropriate chemotherapy 
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without a definitive identification and characterization of the organism collected from the 
patient sputum. The Food and Drug Administration (FDA) permitted marketing of the 
Xpert MTB/RIF assay instrument (Cepheid, Sunnyvale, California) to detect DNA of the 
Mtb complex (MTBC).The instrument can determine genetic mutations associated with 
resistance to rifampin (RMP) in unprocessed sputum and concentrated sputum sediments. 
Test results generated by the instrument in conjunction with clinical, radiographic, and 
other laboratory findings will provide clinicians a comprehensive assessment in the 
diagnosis of pulmonary tuberculosis (CDC, 2013).   
TUBERCULOSIS IN THE PHILIPPINES 
The Philippines with a developing economy located in the south-eastern part of 
Asia composed of 7,107 islands. Based on the 2010 population census data, there are 92.3 
million Filipinos (Vianzon et al., 2013). Based on 2010 national data the Gross Domestic 
Product grew by 7.3%. The geographical location of the country is along the Pacific Ring 
of Fire and typhoon belt. A significant number of people are displaced and killed due to 
several natural disasters that occurred in the country (WHO Western Pacific Region, 
2014). Natural disasters are some of the risks that hinder the steady rate of Philippines 
development; thus the significant proportion of the population remain poor (WHO 
Western Pacific Region, n.d.a). Other health-related risk factors cited by the WHO 
Western Pacific Region are air pollution, water pollution, poor sanitation and unhygienic 
practices and solid waste mismanagement. Further, low-income families living in isolated 
areas are faced with difficulties going to health centers and schools due to inadequate 
infrastructure and economic condition. The HIV prevalence in the Philippines though 
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under 0.1% is rapidly expanding due to men who have sex with men, and injection drug 
users. Besides Tuberculosis, other diseases prevalent in the country are malaria, dengue, 
filariasis, leptospirosis, other diarrheal diseases, and some soil-transmitted helminths 
(WHO Western Pacific Region, n.d.). The diseases above are endemic nationwide. 
Smokers comprise 28.3% of the adult population based on 2009 Global Adult Survey 
conducted in the country. 
TB mortality remains high at 27 per 100,000 populations. TB disease is the sixth 
leading cause of morbidity and mortality in the Philippines. The country is ninth out of the 
22 highest TB-burden countries (WHO, 2014f). The TB disease-causing organism was 
classified as Manila family of Mtb and is a group of clonal isolates seen throughout the 
Pacific Basin (Frink et al., 2011). TB case notification rate in the Philippines of positive 
smear cases from 2003 to 2011was highest in 2006 per 100,000 and experienced a decline 
from 2007 to 2008. An increase observed from 2009 to 2011 but a little below the 2006 
case notification rate (Vianzon et al., 2013). The awareness about the disease is present, 
but the level of understanding of what causes the disease, how it is transmitted, and the 
importance of completing the prescribed treatment is small (PhilPact, 2010-2015). 
A literature review of published studies showed a possible gap of MDR-TB risk 
factor association studies in the country. One such study is a nationwide survey conducted 
in the Philippines with respondents enrolled from June 2003 to November 2004 following 
population-proportionate cluster sampling. The study primary purpose was to determine 
the national level of MDR-TB prevalence against the isoniazid, rifampicin, ethambutol 
and streptomycin (Philippine Nationwide Tuberculosis Drug Resistance Survey Team, 
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2009). The study was conducted for 17 months.  The demographic characteristics obtained 
are; age, gender, place of residence (Philippine Nationwide Tuberculosis Drug Resistance 
Survey Team, 2009). This comprehensive study made use of the Epi Info Version3 
software for data storage and in the determination of drug resistance prevalence. What is 
remarkable in the study was that previously treated cases had 38.8% resistance to the four 
drug identified. The percentage resistance is higher to the 20.4% resistance from not 
treated or new cases throughout the country (Philippine Nationwide Tuberculosis Drug 
Resistance Survey Team, 2009). In addition, most of the respondents, that has been 
previously treated, were resistant to isoniazid followed by rifampicin, streptomycin and 
least resistant to ethambutol (Philippine Nationwide Tuberculosis Drug Resistance Survey 
Team, 2009).  
On the other hand, isoniazid was still observed as the antibiotic of primary 
resistance for new cases followed by streptomycin, rifampicin, and ethambutol (Philippine 
Nationwide Tuberculosis Drug Resistance Survey Team, 2009). Remarkably the findings, 
where Mtb was most frequent drug resistant to isoniazid, was concurred in a study that 
was done on wider year coverage from 2003-2008. The later study found out that among 
new TB cases, most drug resistance pattern is isoniazid and rifampicin. The anti TB drug 
resistance pattern in the country was primarily isoniazid followed by rifampicin with 
fluoroquinolones (Gler, Guilatco, Guray & Tupasi, 2012). The findings from the studies 
above are of great concern to a public health practitioner. Clinicians’ selection for 
antibiotic to treat the disease will be limited. Antibiotic susceptibility testing, to determine 
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the most effective drug that will eliminate the pathogenic organism, will add burden to 
patients. 
The treatment of TB provides an additional economic burden on the country's 
health care system. Fitzpatrick, & Floyd (2012) reported that treatment cost of TB patient 
in the Philippines is $US3, 613. The country a gross national income as of 2003 data is 
only US$1, 080. MDR-TB treatment cost is more expensive since the drug used for 
treatment is considerably higher than drug-susceptible TB cases. Nevertheless, the overall 
cost of MDR-TB treatment in the Philippines is still lower when compared to other 
European countries (Loddenkemper, Sotgiu & Mitnick, 2012). 
Significantly the transmission of this communicable disease in the Philippines does 
not necessarily occur directly from the patient living in close proximity in the same 
household but rather frequently is community-based (Sia et al., 2013). The rapid 
proliferation of the disease not only affects the lungs but as well the eyes that add a burden 
to the patient and decreases economic productivity. Seven out of the 103 pulmonary TB 
patients in the Philippines (6.8% prevalence: 95% CI 2.78% to 13.5%) showed signs of 
ocular inflammation and lesions (Lara, and Ocampo Jr, 2013).   
TB treatment in the Philippines is provided free of charge in government hospitals. 
This does not include another incendiary cost such as transportation to clinic or hospitals, 
food, etc. Besides other cost associated with treatment, socio-ecological barriers to 
treatment can be a factor for the disease to spread within the community. Among which 
are the quality of healthcare services provided, shame associated with TB and familial 
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responsibility accompanying during the treatment period (Hua, Loob, Wincha, &. 
Surkana, 2011). 
The need to control if not stop the proliferation of the disease does not center only 
on the detrimental effect on the physiological health of the infected person but likewise on 
the mental health brought about by depression. In a cross-sectional survey conducted 
among pulmonary TB-infected patient that live in Tondo, Manila Philippines16.8% out of 
the 561 respondents manifested depressive state (Masumoto et al., 2014). The Philippines 
government recognizes the detrimental effect of TB to health and the economic burden 
that the disease brought about to patient and society as a whole. TB Control Program was 
initiated in the Philippines following guidelines provided by the World Health 
Organization in which free treatment is provided through Directly Observed Treatment, 
Short-course (DOTS). The treatment program is managed by the National TB Control 
Program (NTP) of the Department of Health which develops policies and plan. The 
program was implemented in a devolved system down to the lowest structure of 
government starting from the national, regional, provincial, municipal and finally 
Barangay level through a standardized reporting system (Vianzon et al., 2013). However, 
because of budgetary requirements electronic surveillance to develop a central data system 
is not yet fully implemented in the country; thus most clinical case record can be obtained 
through identified DOTS centers. Because of MDR-TB threatens the gains achieved in 
drug-susceptible TB control program through DOTS; the public-private partnership was  
forged, and the incorporation of MDR-TB services into the NTP was required by the  
Department of Health (Quelapio et al., 2010).  
49 
 
 
Chapter 3: Research Method 
The study objective was to assess the strength of the association between possible 
risk factors and development of the MDR-TB infection. Possible risk factors (the 
independent variables) that were considered in this study were (a) previous TB treatment, 
(b) HIV infection, (c) exposure to a drug-susceptible TB/MDR-TB patient, (d) delayed 
diagnosis and treatment, (e) employment status, (f) smoking, (g) imprisonment, (h) 
alcohol abuse, and (i) compliance with drug-susceptible TB treatment regimens. I hope 
that study results provide a basis for public health professionals and other community 
stakeholders to develop effective and proactive intervention programs to enhance the 
prevention of MDR-TB in the Philippines.  
In this Chapter, I provide an overview of the research design I used, which 
includes specific details regarding the method, study population, sample, and sampling 
strategies. The relationships between the study variables are also explained in this chapter. 
Furthermore, I provide a presentation of the statistical treatment of data and ethical 
considerations regarding protection of study participants. 
Research Design and Rationale 
The study applied a quantitative method to assess the strength of the preidentified 
possible risk factor(s) associated with MDR-TB infection. The data that e collected was 
assessed to provide evidence of causality. Specifically, case-control design was used in the 
study. The study subjects were patients who had been clinically confirmed to be MDR-TB 
positive. MDR-TB infection was the dependent variable of the study.  
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The control subjects were selected among patients with drug-susceptible TB and 
clinically confirmed patients with MDR-TB are the cases.  Age, gender, and education of 
control subjects were matched with cases to minimize the effect of confounding. The  
survey questionnaire is the primary instrument for obtaining data from study participants. 
Prior research studies performed by Chen et al. (2013) and Rifat et al., (2014) 
demonstrated that relevant potential risk factors for MDR-TB infection in a particular 
geographic location could be well studied using a case-control design. I identified risk 
factor variables to use as independent variables based on the literature I reviewed in 
Chapter 2. 
Settings and Samples 
The control and possible eradication of MDR-TB in the Philippines is managed by 
the Department of Health National - Center for Disease Prevention and Control through 
the National TB Control Programme (NTP). The central NTP team develops policies, 
standards, and plans and offers guidance for regional, provincial, municipal, and Barangay 
levels of government. The primary purpose is to ensure standardized routine treatment of 
patients through the Directly Observed Treatment, Short-course (DOTS) at designated 
facilities to control the proliferation of the disease (Vianzon et al., 2013). 
Based on geographical location and accessibility of clinics and hospitals, I 
recruited target survey respondents from Programmatic Management of Drug-Resistant 
(PMDT) TB clinics and hospitals and drug-susceptible respondents from town health 
centers that provide DOTS as designated by the National Tuberculosis Program to treat 
MDR-TB and drug-susceptible TB patients. Most of the 2,618 MDR-TB patients 
51 
 
 
nationwide are treated in PMDT clinics located in metro Manila (Philippine Business for 
Social Progress, 2013). One of the PMDT centers is the San Lazaro Hospital, which is 
located in Manila. A municipal health clinic from the town of San Mateo, Rizal, was also 
a source of MDR-TB cases, and most of the controls were recruited from the different 
towns of the province of Leyte such as Burauen, Dagami, Tanauan, Barugo, Capoocan, 
and Carigara. Leyte is part of Region VIII in the Eastern Visayas Island, which is my 
home region.  
Population Inclusion and Exclusion Criteria 
The primary inclusion criteria of the respondents in the case group was that  the 
respondent’s has a documented medical record that M. tuberculosis was detected in 
patient's sputum, and the microbial strain is resistant to either isoniazid or rifampicin. 
Bacterial resistance to antibiotic is determined through drug susceptibility testing 
(Philippine Department of Health -National TB Control Program, 2014). The primary 
inclusion criterion for the control group was that the respondent has a confirmed 
documented medical record indicating the identification of Mtb from the patient’s sputum. 
However, microscopic sputum examination for the presence of Mtb may affect the 
performance characteristics of the control due to potential unrecognition of drug resistant 
Mtb. This was demonstrated in a study performed by Singh (2014) wherein the sputum 
microscopy was observed to be less sensitive and specific (61.54%, 96.57% ) when 
compared to Cartridge Based Nucleic Acid Amplification test for Mtb (82.69%, 98.29%) 
in the same 227 patients. To be eligible, study participants must have checked the agree to 
participate box in the Study Information and Participation Consent form. MDR-TB and 
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drug-susceptible TB patients’ medical records were not accessed and the patients not 
enrolled if the agree to participate box was not checked.  
Main Study Procedure 
Consent from the clinic head was obtained from each PMDT treatment center or 
drug-susceptible TB treatment centers identified (Appendix A). Upon the approval of the 
PMDT treatment center or TB treatment center administrator, the Study Information, and 
Participation Consent that’s translated in Filipino language were offered to potential study 
recruits. To ensure that potential respondent understands the study, I provided an 
individual study orientation in which he/she can freely ask questions and was provided 
ample time approximately 1 hour to make a decision. Alternatively, I facilitated a small 
group study orientation  to allow those who might want to participate to self-select, in 
which they can freely ask questions and were provided ample time approximately 1 hour 
to make a decision. When a recruit volunteered to be a study participant and has signed the 
informed consent, I assigned a study identification number following a standardized 
nomenclature to each study participant. The identification system start’s with the first 
letters of the clinic name, followed by a patient number and Co for control or Ca for the 
case as defined in the study. If the patient ID is, SLHP05Ca meant the respondents came 
from San Lazaro Hospital, patient number five and was classified under the case group 
having diagnosed to be infected with MDR-TB. A password protected Excel central 
database was created with the identity of the respondents. The study identification number 
was written on the questionnaire and the clinical record data extraction form. Each 
questionnaire and the medical extraction form were placed inside an envelope. Then the 
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questionnaire that is in the Filipino language was offered to each participant that signed 
the Study Information and Participation Consent Form. The respondents answered the 
questionnaire in an area designated by the facility. The respondents handed over the 
envelope with the answered questionnaire to the researcher for review and storage. I  
provided a list of the patient to the clinic/hospital and the envelope with the respondent's 
clinical record extraction form. Clinic/Hospital was requested to review the patient clinical 
record to verify whether the patient is either a laboratory confirmed MDR-TB or a 
laboratory-confirmed Drug-Susceptible TB, and the most recent HIV test result (if 
available) and was documented in the Respondents – Clinical Record Extraction Form 
(Appendix B). 
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Figure 7. Schematic diagram of the Main Study Procedure 
 
Sample Size Selection  
Given the need for the researcher to be personally present during interaction with 
the study subjects, due to the geographical location of the Philippines and accessibility; 
the I planned to administer the questionnaire to 50 MDR-TB patients and 50 drug-
susceptible TB patients. However, to determine the ideal sample size, a priori power 
analysis based on chi-square test of independence was conducted to determine the 
minimum sample size required for this study using Gpower 3.1.9.2. Assuming a moderate 
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effect size (Cohen’s w = 0.3) and a significance level of 0.05, the minimum sample size 
required to detect a significant effect with 80% power is 108. Thus, 54 control subjects 
among patients with drug-susceptible Tuberculosis, and 54 cases among patients with 
clinically confirmed MDR-TB was the ideal sample size in this study. 
Data Base Development and Analysis 
The study assessed the strength of the association between the identified possible 
risk factors and MDR-TB infection in the Philippines. Specifically, the study  examined 
whether the following independent variables are associated with MDR-TB infection: (a) 
previous TB treatment; (b) infected with Human Immunodeficiency Virus; (c) exposure to 
drug-susceptible TB/MDR-TB patient; (d) delayed diagnosis and treatment;  
(e) employment status; (f) smoking; (g) imprisonment; (h) alcohol abuse and (i) 
compliance with drug-susceptible TB treatment regimen. 
  This study attempted to answer the null hypothesis that the MDR-TB infection is 
not associated with any of the following possible risk factors as determined by the 
questionnaire: (a) previous TB treatment; (b) infection with Human Immunodeficiency 
Virus; (c) exposure to drug-susceptible TB/MDR-TB; (d) delayed in diagnosis and 
treatment; (e) employment status; (f) smoking; (g) imprisonment; (h) alcohol abuse and (i) 
compliance with drug-susceptible TB treatment regimen. In addition the alternative 
hypothesis in this study is: MDR-TB infection associated with one or more of the 
following possible risk factors as determined by the standardized questionnaire: (a) 
previous TB treatment; (b) infection with Human Immunodeficiency Virus; (c) exposure 
to drug-susceptible TB/MDR-TB; (d) delayed in diagnosis and treatment; (e) employment 
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status; (f) smoking; (g) imprisonment; (h) alcohol abuse and (i) compliance with drug-
susceptible TB treatment regimen.  
Quality Control of Data 
To ensure quality control of data obtained through the following steps were strictly 
followed: 
1. Checked and reviewed the questionnaire that was translated into the Filipino 
language before the study recruit leaves for missing, incomplete or inconsistency 
of information data. 
2. Consistency checked on each questionnaire to determine logic or compatibility of 
the answer to related questions. 
3. A questionnaire with incomplete information or inconsistent information was 
returned before the study recruit leaves to clarify with the study respondents if the 
question was understood. 
4. Study respondents were not required to change the answer to the question if he/she 
does not like to do so.  
5. Each questionnaire was evaluated against the corresponding clinical record to 
ensure the respondents satisfy the inclusion criteria. 
Data was entered immediately in the database and validated. All completed questionnaire 
was kept in a secured file. 
Database Development and Management 
The database was developed by the researcher that contains the independent 
(possible risk factors) and dependent (outcome) variables under consideration in this 
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study. Respondents in the database were identified through the pre-assigned study 
identification number by the investigator. Questionnaire of study respondents with not 
more than three missing data or inconsistent answer was used in the development of the 
database. All questions on the questionnaires were pre-coded as shown in Table 2 to 
facilitate database development and statistical analysis.  
 Quality control check of data entry was done at each stage of data entry through 
verification and cross matching of the response entry of the respondents, linkage of study 
participant study number to the entered data, correct classification of the respondents (i.e. 
case or control) and hospital or clinic source of the respondents. All data entered was 
reviewed and verified to ensure its accuracy before the start of the analysis.  
Table 2 
 
Measurement Level and Coding for Independent Variables 
Variable 
Information 
source 
Variable type 
Measurement level and 
coding  
Previous TB treatment B.10-12 Independent 
Categorical 
1 = Isoniazid (INH) 
2 = Ethambutol (EMB) 
3 = Rifampicin (RIF) 
4 = Pyrazinamide (PZA) 
5 = Others 
6 = Not answered 
Human immunodeficiency 
virus infection 
D.24-25 Independent Categorical 
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Continuation  Table 2 
 
 
  
1 = yes 
 
2 = No 
 
3 = Not answered 
Exposure to drug- 
susceptible TB/MDR-TB 
patient 
A.1-4 Independent 
Categorical 
 
1 = yes 
       2 = No 
 
3 = Don’t Know 
 
4 = Not answered 
Delayed diagnosis and 
treatment 
A.6-8 Independent 
Categorical 
      0 = 1 week or less 
 
1 = 2 weeks 
 
2 = 3 Weeks 
 
3 = A month 
 
4 = Greater than 1 month 
 
5 = I don’t remember 
 
6 = No answer 
Employment status 5 Independent 
Categorical 
1 = Unemployed 
2 = Employed 
3 = Retired 
4 = Not answered 
Smoking F.31-35 Independent Categorical 
   
1 = Occasionally 
   
2 = Daily 
   
3 = Not answered 
Imprisonment E.27-28 Independent Categorical 
   
1 = yes 
   
2 = No 
   
3 = Not answered 
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Alcohol use 
 
G.36-38 
 
Independent 
 
 
Categorical 
1 = Occasional only 
   
2 = Once a week 
3 = Every day     
4 = Not answered 
Compliance with drug  
susceptible TB treatment 
regimen 
B.13-17 Independent 
Categorical 
 
1 = yes 
 
2 = No 
  3 = Not answered 
 
 
Data Analysis 
Statistical Package for the Social Sciences (SPSS) software (IBM Corporation, 
2014) was utilized to facilitate statistical analysis. Description of cases and controls was 
performed by comparing the study respondent’s socio-demographic and clinical risk 
factors as shown in the table below. 
 
Table 3 
 
Case and Control group socio-demographic and clinical risk factors Comparative 
Risk Factors 
All 
Respondents  
N =  
MDR-TB 
Drug-
Susceptible 
TB 
P value 
a)   Previous TB Treatment 
        
      Isoniazid (INH) 
      Ethambutol (EMB) 
      Rifampicin (RIF) 
      Pyrazinamide (PZA) 
      Others 
      Not answered 
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(b) Human  Immunodeficiency 
             Virus Infection 
        Yes 
        No 
        Not answered 
(c) Exposure to drug-  
     Susceptible  
        
     TB/MDR-TB  patient 
        Yes 
        No 
        Don’t Know  
        Not answered 
(d) Delayed diagnosis and        
      treatment 
        
        One week or less   
        Two weeks  
        3 Weeks  
        4 weeks 
        Greater than  1 month 
        I don’t remember 
        No answer 
 
(e) Employment  status  
 
 
 
 
  
       Unemployed 
       Employed 
       Retired 
       Not answered 
(f) Smoking  
        
       Occasionally  
       Daily 
       Not answered 
(g) Imprisonment 
    
      Yes 
      No 
      Not answered 
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(h) Alcohol Use 
       Occasional only 
       Once a week 
       Every day     
       Not answered         
(i) Compliance with drug 
       susceptible TB treatment  
       regimen 
        Yes 
        No 
       Not answered         
 
             Comparative Descriptive Analysis  
Each of the categorical independent variables was tested to assess the statistical 
significance of the association with the dependent variable through the application of the 
chi-square test. A t-test was applied for the independent interval variable. The alpha level 
was 0.05, such that when p< 0.05 it was considered indicative of a statistically significant 
association with the dependent variable. To address the research question and determine 
which of the hypothesis is acceptable, the independent variables or risk factors that have a 
statistically significant association were further analyzed following the odds ratios. 
Participants and Data Protection 
Approval to conduct the research was obtained from the Walden University 
Institutional Review Board.  Ethical issues required by IRB were strictly observed in the 
research process. The researcher does not have any personal biases relative to the study 
that could jeopardize its scientific objectivity; or any conflicts of interest relevant to the 
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research. To ensure confidentiality of participant’s data information the following steps 
were followed: 
1. Participation in the study is voluntary in nature. 
2. Study respondents consent was obtained through an informed consent 
process and signing of the Study Information and Participation Consent form 
translated in the Filipino language. 
3. Study participants were only identified in the questionnaire through Study 
ID Number. 
4. The master database in Excel format was not linked the Study Number to 
the Name of the respondents and was secured through a password accessible only 
by the researcher. 
5. Study records/files were stored in a secured manner for 5-yrs and then 
destroyed.  
6. The data was presented only in aggregated form; no patient identifiers were 
included in any reports of results. 
7. Written permission was obtained from appropriate authority to access the 
data needed for the study. 
8. A two page summary of the study results was provided to each 
hospital/clinic from where the study respondents were obtained which will be 
posted in hospital/clinic public bulletin board. The Philippines Department of 
Health and the World Health Organization’s Regional Office for the Western 
Pacific (located in Manila, Philippines), and the Philippine Tuberculosis Society 
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will also be provided with the two-page summary result. If invited to present the 
study power point presentation will be utilized.  
9. I followed the rules required by the hospital/clinic administration during 
the conduct of the research study. 
The study commenced following the stated methodology of data collection and database 
development, which was approved by the Walden University Institutional Review Board 
(IRB). 
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Chapter 4: Results 
The analysis performed is presented in this chapter in order  to find out if there is 
an association between MDR-TB infection and the following possible risk factors: 
previous TB treatment, infection with HIV, exposure to an unknown TB patient, delay in 
TB diagnosis and treatment, employment status, smoking, imprisonment, alcohol abuse, 
and/or compliance with the TB treatment regimen.   
Chapter 4 will start with the comparative descriptive demographics for Cases and Control 
patients. Univariate and bivariate analysis of possible risk factors are described in each 
section.  
Data Collection 
 Data used in the analyses were gathered from MDR-TB and drug-susceptible TB 
infected respondents using a questionnaire (see Appendix C) that I developed. The 
informed consent and questionnaire were translated into Filipino language or Tagalog by 
the Department of Filipino and Philippine Literature of the College of Arts and Letters, 
University of the Philippines (see Appendix D and E). Permission to conduct the research 
(see Appendix F) was obtained from the Philippine government administered health center 
through the Disease Prevention and Control Bureau of the Department of Health (DOH). 
The study was approved since the research topic is consistent with the research agenda of 
Philippines DOH’s TB program.   
Study respondents for the Control group (drug-susceptible TB patients) were 
recruited from health centers in the towns of Burauen, Tanauan, Capoocan, Barugo, 
Dagami, and Carigara all located in the province of Leyte in Region VIII (Eastern 
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Visayas). Approval from the person-in-charge at each health center or TB program was 
obtained (see Appendix G, H, I, J, K, and L). For some of the MDR-TB patients, I secured 
the town mayor’s consent was secured first because the Mayor's Office also administers 
town health centers. I performed the administration of the questionnaire in November 
2015.  
Data for the cases were collected from the town of San Mateo’s Programmatic 
Management of Drug-Resistant TB Health Center. The town is located in the province of 
Rizal in Region IV-A. Approval from the person-in-charge at each health center or TB 
program was obtained (see Appendix M). Most study participants within the Cases group 
were voluntarily recruited from San Lazaro Hospital in March 2016. The San Lazaro 
Hospital Ethics Review Board endorsed the study (see Appendix N). 
The respondent’s identification system was applied so that critical information of 
participants is not present in the questionnaire and in line with Walden University IRB-
approved research protocol described in Chapter 3. Data were collected and entered into a 
database.  It was originally proposed that only questionnaires with fewer than three 
unanswered items would be considered in the database development. However, this would 
only provide 35 respondents for Control and 43 for Cases, which would not meet the 
minimum of 54 respondents for each group. To avoid selection bias all the 172 
respondents (Control = 93 and Cases = 79) were included in the database development. 
Inclusion of the entire respondents in the data base development provides a better 
understanding and documented justification as to the weakness of the study.  In addition, 
such process provided the foundation for improvements and modifications that will be 
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stated in the recommendation section of the study in case a similar study is conducted in 
the future by another researcher. The statistical analyses were performed using statistics 
described in chapter 3, with the aid of Statistical Package for the Social Sciences (SPSS) 
software.  
Descriptive Epidemiology 
In this section, I summarize the demographic profiles of Cases and Controls 
patients. Sociodemographic characteristics include age, gender, place of birth, education, 
employment status, and source of income.   
Distribution of Controls and Cases. A total of 172 TB patients were recruited. 
The study population is not representative of all MDT-TB and drug-susceptible TB 
patients in the country. The Controls group had 93 respondents who were recruited from 
the different health centers and who voluntarily accepted to answer the study 
questionnaire. In this group, 44.1% respondents were from the town of Burauen. This is 
followed by lesser percentages from the towns of Dagami (16.1%), Carigara and 
Capoocan (12.9%), Tanauan (7.5%), and Barugo (6.5%). The Cases group was composed 
of 79 respondents. Most (88.6%) of the respondents came from the PMDT section of San 
Lazaro Hospital, which was selected as a study site because it is one of the DOH hospitals 
that has been designated to treat MDR-TB. The other respondents were from the health 
clinics of San Mateo, Rizal (3.8%), Barugo and Dagami (2.5%), and Tanauan and 
Capoocan (1.3%).  
The Philippines, being an archipelago, is generally divided into the three large 
islands of Luzon, Visayas, and Mindanao. Based on the last population census, which was 
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conducted in August 2015, Luzon had a population of 57, 470, 097; Visayas, 19,373, 431; 
and Mindanao, 24,135, 775 (Philippine Statistics Authority, 2015). Inquiry with the 
Philippine National TB Control Program Management Office revealed that the MDR-TB 
risk factors that were considered in this study are not obtained as part of data collection on 
the subnational incidence rate of TB.   
The health centers from which Control respondents were recruited are located in 
the province of Leyte, which is part of the Eastern Visayas region of the Philippines. Most 
of the respondents in Controls reside in the province of Leyte, 80.1%. Among these 
respondents, 14.9% were born in Mindanao 4.6% in Luzon. All 79 members of the Cases 
group answered the question regarding place of birth; 87 of the 93 members of the Control 
group did so.  However, 64.6% of respondents in Cases were born in Luzon, which is 
where San Lazaro Hospital is located. Some respondents from Cases were born in 
Mindanao (5.1 %) and Visayas (30.4%). A chi-square test showed a statistically 
significant difference (p < 0.0001) between Cases and Controls regarding place of birth. 
Gender. There were 104 male and 68 female respondents. There were 33 (35%) 
females and 60 (65%) males in the Controls, group and 35 (44%) females and 44 (56%) 
males in the Cases group. More male respondents was recruited for Controls (60) as 
compared to Cases (44). There is only a difference of two female respondents between the 
two study groups. A chi-square test showed that there is no significant difference (p 
>0.05) between gender distribution or gender profile of the Control and Cases. 
Educational Attainment. Comparison of the Cases and Controls respondents 
educational attainment showed a difference between the two groups. The Cases are 
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generally more educated having more respondents completed high school and college 
education.  The prevailing educational attainment of the respondents from the Control 
group is elementary education. The difference in the education profile between Cases and 
Controls is statistically significant when the Bonferrono correction was applied (p = 
0.006) at two levels of education attainment which are elementary and high school.   
Table 4   
 
Educational Attainment for Controls and Cases 
Educational Attainment 
Controls (n = 93) Cases (n = 79) Chi 
square 
p 
value Frequency Percent Frequency Percent 
None 6 6.5 2 2.5  1.48 0.22 
Elementary 70 75.3 33 41.8 19.95 0.00 
High School 0 0 20 25.3 26.64 0.00 
College and Mastersa 17 18.3 24 30.4 3.44 0.06 
 Note: Pearson Chi-Square, X2 = 36.567 
          Degree of freedom = 7 
          Bonferroni's adjustment p < 0.006 
         a In the Cases the data for College & Masters were aggregated for this analysis since  
           only 1respondent has a Master’s Degree and 0 from Controls.  
 
  Table 4 showed that most respondents in the Control group had completed 
elementary education (75.3%), followed by college degree (18.3%), some did not 
complete elementary education (6.5%). Out of the 79 respondents with MDR-TB infection 
2.5% did not complete elementary education which is generally provided free by the 
Philippine government.  Most of the respondents in the Cases completed elementary 
education (41.8%) followed by college and master’s degree (30.4%). The respondents in 
the Cases group that completed high school education is 25.3%, and those that did not 
complete the free elementary education is 2.5%.   
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Age Profile. Table 5 and Figure 8, show that in the Control group the respondent’s 
age, ranged from 18 to 89 years old (Mean = 50.8, Std. Dev = 17.4). The male 
respondent’s minimum and maximum age are 18 and 80 years old respectively with a 
Mean of 49.7 and Standard Deviation of 16.2. The female respondent’s minimum and 
maximum age are 19 and 86 respectively, with a Mean of 52.9 and Standard Deviation of 
19.3. The t- test showed that there is no statistical difference (p = value 0.25, t = 0.8373, df 
= 91) among the female and male respondents age in the Control group.  
The male respondents in the Cases had a minimum and maximum ages of 18 and 
71 respectively, with a Mean of 43.1 and Standard Deviation of 13.6.  However, among 
the females, 19 and 63 are the minimum and maximum ages respectively. The Mean age is 
35.7 with a Standard Deviation of 12.8. Statistical analysis showed that there is a 
difference (p = value 0.02, t = 2.4602, df = 77) among the female and male respondents in 
the Case group with females statistically significantly younger than the males. 
It was observed that MDR-TB respondents are of younger age compared to Drug 
Susceptible TB (Table 5 and Figure 8). The Cases are younger with a Mean age of 39.8 
while the Control is 50.8 (t-test, p<0.001).  
Table 5  
 
Age Distribution of Controls and Cases 
Age 
Group 
(years) 
Controls ( n = 93)   Cases (n =  79) 
   
Percent 
Cumulative 
Percent 
  Percent 
Cumulative 
Percent 
18-23 7.5 7.5 
 
13.9 13.9 
24-29 5.4 12.9 
 
13.9 27.8 
30-35 9.7 22.6 
 
16.5 44.3 
70 
 
 
Continuation Table 5 
 
36-41 9.7 32.3 
 
11.4 55.7 
42-47 11.8 44.1 
 
13.9 69.6 
48-53 10.8 54.8 
 
12.7 82.3 
54-59 10.8 65.6 
 
10.1 92.4 
60-65 12.9 78.5 
 
3.8 96.2 
66-71 7.5 86 
 
3.8 100 
72-77 7.5 93.5 
   
78-83 5.4 98.9 
   
84-89 1.1 100       
Summary 
Mean: 
50.8 
Std. Dev:  
        17.3 
  
     Mean: 
39.8 
Std. Dev:     
13.7 
Note:   t test = 4.5817 
            95% CI of 6.29 - 15.81 
          p-value = < 0.001 
         Statistically significant difference in the age profile of the Controls and Cases.  
 
Figure 8. Age of Cases and Controls 
Note:  Drug Susceptible TB Mean Age = 50.8  
                                                Std. Dev. = 17.3 
           MDR-TB Mean Age = 39.8  
                            Std. Dev. = 13.7 
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Employment Status and Sources of Livelihood.  High unemployment was 
observed in both Cases and Controls, most of the 93 Controls reported being unemployed 
and retired (79.6%) and only 18.3% employed (Table 6). However, in the Cases the 
unemployed and retired is 82.3% with the employed 17.7%. Two Controls did not disclose 
their employment status. There is no statistically significant difference in employment 
status between the Control and Cases (p > 0.88).  Two respondents that did not indicate 
their employment status were not included in the analysis. 
Table 6 
 
Employment Status of Controls and Cases 
Employment Status 
Controls (n = 93)    Cases (n = 79) 
Frequency Percentage Frequency Percentage 
Unemployed and Retireda 74 79.6 
  
65 82.3 
 
Employed 17 18.3 
 
14 17.7 
No Answer 2 2.2   0 0 
Note: t test = 0.1581 
          95% CI of -77.28-86.61 
          p-value = >0.88 
   
Data analysis showed only 17 Control and 14 Cases   (18.0% of 172 study 
subjects overall who provided employment information -- see Table 7) had full time 
source of livelihood. The primary reasons for unemployment among Controls are 
health condition and unavailability of employment opportunities in the area.  
Only 31 study subjects provided employment income information (14 Cases and 
17 Controls). Most of the employed Cases (35.7%) as shown in Table 7 work for various 
jobs (i.e. furniture working, laborer, a pedicab driver, campaign staff, electrician, sales 
lady, taxi driver and vendor) as source of livelihood.   However, one Case did not disclose 
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the source of livelihood. Fishing/Farming is the predominant source of livelihood among 
the employed Controls (52.9%) while Driver (28.6%) and Employment Income (28.6) 
were most common among the Cases. The probable reason Fishing/Farming is the 
predominant source of livelihood among the respondents in the Controls, is that the towns 
in Leyte where the respondents were recruited are either coastal or agricultural area. 
Driver and Employment income is the predominant livelihood of the Cases because the 
majority of the respondents were from San Lazaro Hospital. The hospital is located in 
Manila, a highly populated urban area, and the capital city. Thus this employment profile 
is consistent with that setting. 
Table 7  
 
Controls and Cases that Provided Employment Information 
Sources of Livelihood 
Control (n = 17)   Cases ( n= 14) 
Frequency Percent   Frequency Percent 
Business/Employment 
Income 
2 11.8 
 
4 28.6 
Fishing/Farming 9 52.9 
 
1 7.1 
Driver 0 0 
 
4 28.6 
Others 6 35.3   5 35.7 
Note: Pearson Chi-Square, X2 = 11.460 
          Degree of freedom = 7 
          p-value = 0.12 
          Others include: Furniture Making, Laborer, Painter, Pedicab Driver, Campaign  
                                   Staff, Electrician, Sales Lady, Taxi Driver, and Vendor 
 
The result of the Pearson Chi-Square test indicates there is no statistically 
significant difference between the ages of the respondents in the Controls and Cases 
relative to their employment status (Table 8).  Among the Controls, only 17 respondents 
are employed; five were between ages 48 to 53. This could be attributed to their health 
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conditions and unavailability of job opportunity in the area where the Control respondents 
reside.  The data in Table 8 revealed that of the total 14 respondents who are employed in 
the Case group; six were between ages 18-35. This could be attributed as well to their 
health conditions and unavailability of job opportunity in the area where the Cases 
respondents reside. 
To compare the age of controls and cases in relation to employment status, raw 
data for age was utilized to perform the t test. The t test results indicated the following 
conclusions: the mean age of employed and unemployed respondents is not statistically 
different from both Controls and Cases, and the mean age of Cases is lower than the mean 
age of Controls for both employed and unemployed. 
Table 8  
 
Comparative Age Group Distribution Between Controls and Cases in Relation to 
Employment Status 
 Age 
(years) 
Controlsa,c   Casesb,d 
       Unemployede 
              (n = 72) 
Employedf  
(n = 17) 
  
Unemployede 
(n = 60) 
Employedf  
(n = 14) 
18-23 7 0 
 
10 1 
24-29 5 0 
 
8 3 
30-35 8 1 
 
10 2 
36-41 7 2 
 
7 2 
42-47 10 1 
 
6 4 
48-53 4 5 
 
8 1 
54-59 8 2 
 
8 0 
60-65 8 3 
 
2 0 
66-71 6 1 
 
1 1 
72-77 5 1 
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78-83 4 1       
Mean Age 48.8 55.4   38.9 38.9 
St.Dev Age 17.8 12.7   13.5 12.7 
Note:                                                              
          a Relationship of Age to Employment status of Controls  
                  Pearson Chi-Square, X2 = 12.326                     
          Degree of freedom = 10                                                
          p - value= 0.26 
       b  Relationship of Age to Employment status of Cases 
          Pearson Chi-Square, X2 = 0.99                                                                                                                                                            
          Degree of freedom = 8 
          p - value = 0.42                                                   
       c  Comparison of Age between Unemployed and Employed Controls 
          t = 1.43                                                               
          df = 87                                                                
          CI= -15.68 to 2.56                                              
           p - value = 0.16                                                     
          d  Comparison of Age between Unemployed and Employed Cases 
               t = 0.007 
          df = 72 
          CI= - 7.93 to 7.88 
          p - value= 0.99 
        e Comparison of Age between Unemployed Cases and Controls 
t = 3.622                                                              
df = 130                                                              
CI= 4.35 to 15.43                                              
p - value = 0.001                                                    
f  Comparison of Age between Employed Cases and Controls  
t = 3.579 
          df = 29  
CI= 7.04 to 25.81 
p - value= 0.001 
 
Hypothesis Testing 
The research question in the study is to find out if there is an association between 
MDR-TB infection and the following possible risk factors: Previous TB Treatment, 
Infected with Human Immunodeficiency Virus, exposure to drug-susceptible TB/MDR-
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TB patient, delayed in diagnosis and treatment, employment status, smoking, 
imprisonment, alcohol abuse, and compliance with TB treatment regimen.   
The null hypothesis (H0) and alternative hypothesis (H1) were formulated to 
objectively identify which of these possible risk factors are associated with MDR-TB 
infection. The 0.05 alpha or pre-set level of statistical significance was used to which all 
the p-values were compared to determine whether or not to reject the null hypothesis.  
Analysis of probable risk factors for Multi-Drug Resistant TB infection was done 
consistent with the Case-Control design. The Cases are respondents with MDR-TB and 
Controls are the respondents with Drug Susceptible TB. Comparison of these risk factors 
was made between Cases and Controls.  
Table 9 shows the results of the assessment whether there is an association of the 
pre-identified potential risk factors in this study to MDR-TB infection. Chi Square test 
was used for risk factors with large cell sizes, i.e. Previous TB treatment, Delayed 
Diagnosis, Exposure to Drug Susceptible TB/MDR-TB patient, Smoking, Compliance 
with drug susceptible TB treatment regimen and Employment Status. Fisher exact test was 
used for risk factors with small cell sizes or whose expected values are less than 5, i.e. 
HIV, Imprisonment and Alcohol Use. Though it is desirable not to have missing data; 
missing data are almost present in all quantitative studies (Dong and Peng 2013, Zhu, 
Ibrahim and Tang 2014). The most prevalent reason for incomplete data is item non-
response. This would mean that incomplete information collected from a respondent in 
which case in this study was; refusal of the respondent to provide information in the 
questionnaire due to personal reasons, which was respected by the researcher. In this study 
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missing data was handled following list wise deletion (where the study subject's record 
was excluded from analysis if an essential data element was missing). This means that 
complete analysis was performed on answered risk factor while excluding those that were 
not answered. This approach of dealing with missing data reduced the sample size 
available for analysis, but provided an unbiased parameter estimate (Dong and Peng, 
2013).
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Table 9  
 
Candidate Risk Factors p value Between Cases and Controls 
Risk Factors All Respondents MDR-TB Drug Susceptible TB 
P  value  
Chi-Square 
Test 
Fisher Exact Test 
a)   Previous TB Treatment N = 62 n = 26 n = 36 
0.3 
  
       Isoniazid (INH) +  
5 (8.06) 2 (7.69) 3 (8.33) 
 
       Ethambutol  
 
       (EMB)- Baseline 
 
       Rifampicin (RIF) 47 (75.81) 22 (84.64) 25 (69.44) 
 
       Pyrazinamide (PZA) 10 (16.13) 2 (7.69) 8 (22.22) 
 
(b) Human   Immunodeficiency Virus   
   N = 120   n = 73           n = 47   
0.15 
      infection 
        Yes 4 (3.33) 4 (5.48) 0 (0.00) 
         No 116 (96.67) 69 (94.52) 47 (100.00) 
(c) Exposure to drug-susceptible TB/MDR-  
      TB Patient 
N = 102 n = 42 n = 60     
        Yes 52 (50.98) 26 (61.9) 26 (43.33) 
0.33   
        No 50 (49.02) 16 (38.1) 34 (56.67)   
(d) Delayed diagnosis and treatment   N = 109 n = 44 n = 65   
0.91 
  
      One week or less  - Baseline 26 (23.85) 11 (25.00) 15 (23.08) 
 
        Two weeks  27 (24.77) 12 (27.27) 15 (23.08) 
 
        3 - 4 Weeks  17 (15.60) 7 (15.91) 10 (15.38) 
 
        Greater than  1 month 39 (35.78) 14 (31.82) 25 (38.46)   
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(e) Smoking  
     
       Occasionally  14 (21.21) 4 (11.43) 10 (32.26) 
 0.04* 
 
       Daily 52 (78.79) 31 (88.57) 21 (67.74)   
 
 
 
 
Continuation Table 9  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes:  
            * Statistically significant, p – value < 0.05. 
            a 1respondent from Controls and 0 from Cases that answered; others were excluded from the Chi Square test calculation.  
            b Multiple responses (42 from Cases and 0 from Controls) were not included in the calculation. 67 respondents did not answer  
              the question on previous TB treatment. 
                  c 52 respondents did not answer the question on HIV testing.  
            d 70 respondents did not answer the question on exposure to Drug-susceptible TB/MDR-TB patient. 
            e The “Don’t remember response” excluded 9 (Cases) and 10 (Controls) from the Chi Square test calculation. 44 respondents did  
(f) Imprisonment h N = 153 n = 66 n = 87 
  
      Yes 10 (6.54) 5 (7.58) 5 (5.75) 
  
0.75 
      No 143 (93.46) 61 (92.42) 82 (94.25)   
(g) Compliance with drug susceptible                   
TB  treatment regimen  
N = 127 n = 70 n = 57 
0.001* 
  
      Yes 107 (84.25) 52 (74.29) 55 (96.49) 
 
      No 20 (15.75) 18 (25.71) 2 (3.51)   
(h) Alcohol Use  N = 102 n = 42 n = 60 
 
      Occasional Only + Once a week 94 (92.16) 37 (88.1) 57 (95.0)   0.27 
       Everyday 8 (7.84) 5 (11.90) 3 (5.00)     
(i) Employment Status N = 170 n = 79 n = 91 
0.87 
 
       Unemployed + Retired 139 (81.76) 65 (82.28) 74 (81.32) 
 
       Employed 31 (18.24) 14 (17.72) 17     (18.68)   
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              not answer the question of delayed diagnosis and treatment. 
            f Combined the 3weeks and 4 weeks in the calculation for Chi Square, since no (0) respondent from Control was delayed in  
              diagnosis and treatment for 3 weeks. 
            g 106 respondents did not answer the question on smoking.                         
            h 19 respondents did not answer the question on imprisonment. 
            i 45 respondents did not answer the question on Compliance with drug susceptible TB treatment regimen. 
            j 70 respondents did not answer the question on alcohol use. 
            k 2 respondents from Controls did not provide employment status information.
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The Chi-Square test results as shown in Table 9 revealed that previous TB 
treatment with p-value of 0.30 is not a significant risk factor for MDR-TB infection. The 
68 respondents that did not answer on previous TB treatment question were not included 
in the calculation.  The 42 Cases with multiple responses to the question (previous TB 
treatment) and 0 from Controls is consistent with the Cases having been previously 
treated for Drug susceptible TB. Multiple responses were also not included in the analysis 
since this is only selected by Cases and not by Controls. TB treatment in the Philippines 
is provided by the Department of Health free of charge through the various town health 
centers and government hospitals. The drug treatment formulation could be fixed-dose 
combination (HR-Isoniazid and Rifampicin, HRE-Isonizid, Rifampicin and Ethmbutol, 
HRZE- Isonizid, Rifampicin, Pyrazinamide and Ethmbutol ) or single drug formulation 
which could be either as tablet, syrup or injectable (Streptomycin) form (Philippine 
Department of Health- Manual of Procedures for the National TB Control Program, 
2013).  
HIV as a risk factor for MDR-TB infection is shown not to be statistically 
significant (p = 0.15). The 52 respondents that did not indicate in the questionnaire if they 
have been tested for HIV were not included in the calculation. Data showed that in the 
study population, 4 from Cases were found to be HIV positive compared to 69 which are 
HIV negative.  The HIV data was confirmed by the healthcare provider through the 
Clinical Record Extraction Form designed for this study. The 52 respondents that did not 
indicate if they have been tested for HIV were confirmed by the health care provider. 
HIV testing for TB patient is generally not required in the Philippines. To be tested for 
81 
 
HIV the TB patient should be 15 years old and above and either live in pre-identified 
high priority for HIV or belong to a high-risk clinical groups. This policy is anchored on 
the fact that laboratory testing services are centralized in urban areas, inadequate logistics 
and death rate is not high in TB-HIV target areas (Philippines Department of Health-
National TB Control Program, 2014). Refer to page 85 for further discussion of this 
issue. 
Exposure to Drug-susceptible TB/MDR-TB patient as a risk factor for MDR-TB 
infection is shown in Table 9 as not statistically significant (p - value = 0.33). Survey 
showed that in Cases, the exposure to Drug-susceptible TB/MDR-TB infected person was 
described by Cases as being from friends with once in a while contact (7), house mate 
with every month contact (14), house mate with once in a month contact (3) and work 
place with once in a while contact (2). Among Controls, exposure to Drug-susceptible 
TB/MDR-TB patient was described by Controls as being from: house mate with every 
month contact (4) and with once in while contact (10), friend with once in while contact 
(5), work place with once in a while contact (4), cockfighting arena with once in a while 
contact (1), store with once in a while contact (1), and 1 respondent did provide the 
source and frequency of contact to the person with TB  that might have cause the 
respondent to get infected with the disease. As shown in Table 10, a total of 52 
respondents answered yes to the TB/MDR-TB contact or exposure question while 50 
respondents answered no. However out of the 172 respondents in the study, 70 
respondents did not answer the questions on Exposure to Drug-susceptible TB/MDR-TB 
patient; making it susceptible to possible bias. Delayed diagnosis and treatment as a risk 
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factor for MDR-TB infection as shown in Table 9 is not statistically significant (p = 
0.91). It was observed that most of the respondents (35.78%) sought medical diagnosis 
and treatment after more than a month of experiencing the signs and symptoms of TB.  
This finding is reflective of the Department of Health -National TB Control Program, 
updated 2010-2016 Philippine Plan of Action to Control Tuberculosis wherein it states 
that the TB smear-positivity rate is only 15% nationally, with a wide variance of over 
30% from the test results provided by the various Local Government Unit Health Centers. 
The report attributed the low national TB smear-positivity rate due to lack of TB 
symptoms awareness, unwillingness to provide sputum for M. tuberculosis diagnosis, and 
most likely case findings, in general, is not yet as rigorous compared to other countries 
because of resource limitation. The Philippines TB smear-positivity rate is lower 
compared to a smear positivity meta –analysis study done among pediatric and adult TB 
patient wherein pediatric TB cases, the TB smear-positivity rate of 6.8% and 52.0% 
among adult TB cases in 14 countries (Kunkel et al., 2016).   One potential reason cited 
why the smear-positivity rate is low in the Philippines was that the standardized staining 
protocols are not available at the peripheral level resulting in variable practices that 
impact on overall smear quality and results in addition to the not fully functional quality 
assurance system for smear microscopy (Philippines Department of Health -National TB 
Control Program, 2014). The key to TB control is early detection before it progresses into 
the contiguous state. One of the limitations of the direct smear using the sputum was that 
it could not detect the presence of paucibacillary TB. The presence of paucibacillary 
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bacteria is below the detection limit in direct smear test, this lead into a smear-negative 
result among pediatric, extra pulmonary tuberculosis (Restrepo; et.al, 2006). 
Among the 44 Cases who answered the question (if they seek immediate medical 
help upon experiencing TB infection symptoms) only 8 indicated the reasons while 36 
did not answer the question. The reasons respondents provided for not immediately 
seeking medical attention are: no money for transportation (1), ashamed of the infection 
(1), works (2), No budget or money (4). A total of 65 Controls answered the question. 
However only 8 indicated the reasons why they did not seek immediate medical help. 
The reasons given were: did not mind the symptoms (1), don’t know of TB symptoms 
(1), forgetfulness (1), financial (2), no money for transportation (1), going to die anyway 
(1), and don’t know that coughing is one of the TB infection symptoms (1).  
Smoking was found to be associated with MDR-TB infection as shown in Table 9 
(p = 0.04). Data indicated that the null hypothesis which is smoking is not a risk factor 
for MDR-TB infection is rejected. However, Bonferroni correction was not performed 
because there is no risk of type 1 error (rejecting the null when the null is, in fact, true) 
since there were only two categories of comparison on the frequency of smoking which is  
occasionally and daily  (Lesack and Naughler, 2011). 
The total study population that reported being a smoker before TB infection was 
66. Some respondents smoke daily (52 respondents), while some on an occasional basis 
(14 respondents). Data showed that out of the 93 Cases, and 79 Controls in the study 
population, 58 and 48 respectively did not answer the question if they are smoking before 
infected with TB.  
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A total of 10 respondents in the study population reported having been imprisoned 
while 143 did not experience imprisonment.  The SPSS results for imprisonment (Table 
9) as a potential risk factor candidate for MDR-TB infection, showed that it is statistically 
not significant (p = 0.75).  
Compliance with drug susceptible TB treatment regimen as a risk factor is 
associated with MDR-TB infection (p = 0.001). Data indicated that the null hypothesis 
which is compliance with drug susceptible TB treatment regimen is not a risk factor for 
MDR-TB infection is rejected. However, Bonferroni correction was not performed 
because there is no risk of type 1 error (rejecting the null when the null is, in fac,t true) 
since there were only two categories of comparison which are yes and no (Lesack and 
Naughler, 2011). A total of 107 respondents both from Cases (52) and Controls (55) 
reported complying with the TB treatment regimen which is administered through the 
DOT (Directly Observed Therapy). It was observed that out of the 172 total study 
respondents, 45 (9 Cases, 36 Controls) did not answer on compliance with TB treatment 
regimen.  However, 18 MDR-TB respondents did not previously follow the drug 
susceptible TB treatment regimen for various reasons. Five did not indicate the reasons 
for not following the TB treatment regimen while 13 gave the following reasons: work 
schedule (1), financial (1), drug side effect (1), feel lazy (2), shy for people to know about 
the infection(1) , was told by the doctor to stop for a reason that the respondent don’t 
remember (1), health care provider not strict(1), vomited blood after 5 months(1), no 
money (1), no more coughing(1),  still feel ok (1) and feels ok after taking some of the 
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treatment (1). Thought TB infection is gone and cannot sleep were the reasons cited by 
two Control respondents for not complying with the treatment regimen.  
The Fisher Exact test result for alcohol use (p = 0.27) and Chi-square test result 
for employment status (p = 0.87) (Table 9) as a potential risk factor candidate for MDR-
TB infection showed not statistically significant. Data showed that more respondents 
from Controls (43) drink alcohol occasionally than the Cases (27).  More respondent in 
the study population (139) are either unemployed or retired when compared to those who 
are employed (31).  
This study aimed to determine if the identified risk factors were associated with 
MDR-TB infection.  The association was measured using Odds Ratio (OR) in which the 
precision is estimated by the value of the 95% Confidence Interval (CI). Thus if the OR 
between Cases and Controls groups is 1, this indicated that there was no difference 
between the two groups relative to the risk factors under consideration. However, if the 
OR is > 1, this indicates that the risk factor under consideration affects an increase in 
Cases rather than Control, and vice versa if the OR is < 1.  If the CI is narrow, OR is 
more precise when compared to a CI value that is broader (Szumilas, 2010).  
A validation of the Chi Square statistical results was performed using the Odds 
Ratio (Table 10) which is the ideal statistical test for Case Control design. Results 
showed that the OR values and Chi-Square test results are consistent with each other, that 
is, possible risk factors deemed significant based on the Chi Square test have OR 95% CI 
which do not contain 1. 
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Table 10  
 
Candidate Risk Factors Odd Ratio to MDR-TB Infection 
            Risk Factors Odds Ratio 
95% CI 
Lower Upper 
a)   Previous TB Treatment a 
   
      Isoniazid (INH) + Ethambutol (EMB) – Baseline 
  
      Rifampicin (RIF) 1.32 0.202 8.639 
      Pyrazinamide (PZA) 0.375 0.035 3.999 
(b) Human   Immunodeficiency  Virus infection 
0 0 0 
        Yes – Baseline 
        No 
(c) Exposure to drug-susceptible TB/MDR-TB Patient 
0.471 0.21 1.053 
        Yes – Baseline 
        No 
(d) Delayed diagnosis and treatment b     
        One week or less  - Baseline 
  
        Two weeks  1.091 0.368 3.235 
        3 - 4 Weeks c  0.955 0.276 3.299 
        Greater than  1 month 0.764 0.276 2.11 
(e) Smoking d 
3.69* 1.021 13.341        Occasionally – Baseline 
       Daily 
(f) Imprisonment 
0.744 0.206 2.684         Yes – Baseline 
        No 
(g) Compliance with drug susceptible TB   treatment     
   
      Regimene 
   
        Yes – Baseline 9.519* 2.104 43.059 
        No       
(h) Alcohol Use 
   
       Occasional Only + Once a Week – Baseline 2.568 0.579 11.392 
       Everyday       
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Continuation Table 10 
 
(i) Employment Status       
       Unemployed + Retired – Baseline 0.938 0.429 2.049 
       Employed       
 
Notes: * Significant in Chi-Square p value < 0.05 
                a1 respondent from Controls and 0 from Cases that answered Other was excluded  
             from the Odds Ratio calculation.  
           b The Don’t remember response 9 (Cases) and 10 (Controls) were excluded from  
              the Odds Ratio calculation. 
          c Combined the 3weeks and 4 weeks in the Odds Ratio, since no (0) respondent  
             from Control was delayed in diagnosis and treatment for 3 weeks.  
               d  Drug Susceptible TB patients who are daily smokers is 3.69 x more likely to  
             have MDR-TB infection than occasional smokers. The OR is statistically greater  
             than 1 because the 95% CI does not  contain 1.   
          e  Drug Susceptible TB patient who does not comply with the treatment regimen is   
             9.519 x more likely to have MDR-TB infection than those who comply with the  
             Drug Susceptible TB Treatment Regimen. The OR is statistically greater than 1  
             because the 95% CI does not  contain 1.   
 
 
Based on the Chi-Square test in Table 9, the 2 significant risk factors for MDR-
TB infection were: Smoking (p - value = 0.04) and Compliance with drug susceptible TB 
treatment regimen (p - value = 0.001). The same two risk factors as shown in Table 10 
have 95% confidence interval not containing 1, i.e. Smoking (1.021, 13.341) and 
Compliance with drug susceptible TB treatment regimen (2.104, 43.059).Drug 
susceptible TB patient who are daily smokers (OR 3.69) are three times more likely to 
develop  a MDR-TB infection than those who smoke occasionally. Additionally, 
respondents who did not comply with or adhere to drug susceptible TB treatment regimen 
(OR 9.519) are nine times more likely to develop a MDR-TB infection than those who 
regularly follow the treatment for drug susceptible TB infection.   
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Summary 
This research attempted to answer the research questions (s) if there is association 
between MDR-TB infection and the following possible risk factors: (a) previous TB 
treatment, (b) infection with Human Immunodeficiency Virus, (c) exposure to TB patient, 
(d) delayed TB diagnosis and treatment, (e) smoking, (f) imprisonment, (g) compliance 
with the TB treatment regimen, (h) alcohol abuse, and (i) employment status.  The data 
presented in this chapter using Chi Square test was applied to risk factors with large cell 
sizes, i.e. Previous TB treatment, Delayed Diagnosis, Exposure to Drug Susceptible 
TB/MDR-TB patient, Smoking, Compliance with drug susceptible TB treatment regimen 
and Employment Status. Further, Fisher exact test was used for risk factors with small 
cell sizes or whose expected values are less than 5, i.e. HIV, Imprisonment and Alcohol 
Use.  
Given the data collected from the study, results showed that smoking and 
compliance with drug susceptible TB treatment regimen are the potential risk factors 
associated with MDR-TB infection. The data in this study indicated that drug susceptible 
TB respondents who do not comply with anti TB treatment regimen are nine times more 
likely to develop MDR-TB when compared to those who regularly follow the treatment 
regimen. Further, it was also found out from the analysis of the data that drug susceptible 
TB respondents who smoke on a daily basis is three times more likely to develop a MDR-
TB infection. It is reasonable that smoking is a risk factor for MDR-TB infection, 
because one of the general adverse effects of smoking to the body includes inflammation 
and which impairs immune function (Center for Disease Control and Prevention (2014). 
89 
 
The ability to fight infectious disease such as MDR-TB of a person with impaired 
immune system is compromised or entirely absent. Data in the study indicated that risk 
factors such as previous TB treatment, infection with Human Immunodeficiency Virus, 
exposure to TB patient, delayed TB diagnosis and treatment, imprisonment, alcohol 
abuse, and employment status were not associated with MDR-TB infection. Discussions, 
recommendations, potential social implications as well as the recommendations for 
further research are discussed in Chapter 5.
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Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of this quantitative study was to find out if there is an association 
between MDR-TB infection and the following possible risk factors: (a) previous TB 
treatment, (b) infection with HIV, (c) exposure to a TB patient, (d) delayed TB diagnosis 
and treatment, (e) smoking, (f) imprisonment,  (g) compliance with the TB treatment 
regimen,( h) alcohol abuse, and (i)employment status. The study was anchored in the 
epidemiological theory of John Snow. He pioneered the epidemiological approach to 
causal inference work with an emphasis on the evaluation of preventive, ameliorative, 
and curative interventions (Fine et al., 2013). The theory provided an understanding of 
the agent, the environment, and the host as a framework for the dynamics of disease 
transmission. 
A case-control design was followed, wherein MDR-TB respondents were 
assigned to one group (Cases) and drug-susceptible TB respondents to another group 
(Controls). Data were obtained using a self-administered survey questionnaire that I 
designed for the study. The questionnaires included demographic information and risk 
factors sections. Controls and Cases were selected based on the eligibility criteria 
mentioned in Chapter 3. They voluntarily participated in the study. 
Members of the Controls group were from towns of Burauen, Dagami, Carigara, 
Capoocan, Tanuan and Baguro. The towns are located in the Visayas region of the 
Philippines. The majority (88.6%) of the Cases were from the PMDT section of San 
Lazaro Hospital, which is one of the hospitals designated by the Philippine Department of 
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Health hospitals to treat MDR-TB patients. Some of the Cases respondents were recruited 
from the health clinics of San Mateo, Rizal, Barugo and Dagami, and Tanauan and 
Capoocan.  
It was originally proposed that only questionnaires with less than three 
unanswered items would be considered in the database development. However, because 
of logistic problems in obtaining more respondents, potential selections bias, and to better 
provide justification as to the weakness of the study, all answers from the 172 study 
respondents (93 Controls and 79 Cases) were included in the analyses.   
Statistical analysis using chi-square and Fisher Exact tests and Odd Ratio were 
performed. Complete data analysis was performed concerning risk factors. The results of 
the multiple regression analysis show that smoking and compliance with drug susceptible 
anti TB treatment regimen were associated with MDR-TB infection. Drug susceptible TB 
respondents who smoke daily are three times (OR 3.690) more likely to develop a MDR-
TB infection. Similarly, drug-susceptible TB respondents who do not comply with the 
treatment regimen are nine times (OR 9.519) more likely to develop a MDR-TB 
infection. Risk factors such as previous TB treatment, infection with HIV, exposure to 
TB patient, delayed TB diagnosis and treatment, imprisonment, smoking, alcohol abuse, 
and employment status were not associated with MDR-TB infection (see Table 10). 
Interpretation of the Findings 
Data in this study suggest that the type of anti TB drug that the respondents had been 
previously taking is not a significant risk factor (p = 0.30) for MDR-TB infection. 
Conversely, as discussed in Chapter 4, Mtb drug resistance to anti-TB medicine was 
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identified among patients with relapse treatment to Streptomycin in 1944 (Keshavjee & 
Farmer 2012). The drug resistance was attributed to the disruption of the drug mechanism 
target for bacterial protein synthesis (Goldberg, Siliciano, & Jacobs, 2012). WHO in 1994 
initiated the Global Project on Anti-Tuberculosis Drug Resistance Surveillance to track 
the prevalence of Streptomycin resistance.  Project developers systematically collected 
and analyzed data from 114 countries that reported first-line anti-TB drug resistance 
(WHO, 2009). WHO data showed that the highest level of anti-TB drug resistance is in 
Europe (WHO, 2010) 
From the biological mechanism aspect, one has to consider the ability of the 
organism to develop mutation or evolution, if the TB patient is taking substandard, 
falsified anti-tuberculosis drugs, and failure to follow the prescribed treatment regimen. 
The presence of substandard, falsified first line anti-tuberculosis drugs such as isoniazid 
and rifampicin is present in Africa (10.1%), India (10.1%) and other middle-income 
countries (3.9%; Bate et.al, 2013). The Philippines Food and Drug Administration 
detected in 2012 a substandard first line anti TB drug that was part of the fixed dose 
combination procured from a local manufacturer (Philippine Department of Health -
National TB Control Program, 2014). 
To avoid possible mutation or evolution of the Mtb organism into a drug-resistant 
strain, Zhao et. al. (2012) and Chen et al. (2013) underscored the importance of a high-
quality standard antibiotic treatment and a strict follow-up to ensure adherence by 
patients to the prescribed regimen. Though DOTS is implemented in the Philippines, the 
Joint Program Review observed that in some areas of the country irregular treatment 
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increased the risk of drug resistenace (Philippine Department of Health -National TB 
Control Program, 2014).  
The 172 respondents in this study, only 104 and 68 respondents answered and did 
not answered respectively, the question on previous TB treatment,which may have biased 
the study findings. The Chi-square test showed that there is no statistical significance 
difference (p = 0.89) between the Cases and Controls of the respondents that answer the 
question in relation to previous TB treatment. The researcher expected the respondents 
from the Controls to select no as an answer in the questionnaire especially for first time 
diagnosed with Drug Susceptible TB. However, some respondents refused to answer the 
questions despite the explanation provided by the researcher during the review of the 
questionnaire. As a matter of ethical consideration refusal of the respondents to provide 
an answer to an item in the questionnaire was profoundly respected by the researcher.  
The aforementioned finding is not similar to the studies performed by Daniela and 
Osmand (2011), and Skrahina et. al., (2013), wherein previous TB treatment is a risk 
factor for MDR-TB infection in a study done in South West Nigeria and Belarus 
respectively. 
An immunocompromised patient such as those with HIV is highly susceptible to 
TB infection which results in TB being a common comorbidity of HIV infection. To 
better manage coinfection, WHO requires that key populations have the same access to 
tuberculosis (TB) prevention, screening and treatment services as other populations at 
risk of or living with HIV (WHO, 2016).  In the Philippines HIV testing among TB 
patient is required among patient above 15 years old, living in pre-identified priority 
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areas and belong to high risk group (Philippines Department of Health-National TB 
Control Program, 2014). The aforementioned PDOH policy is not aligned with the WHO 
guidelines regarding routine HIV testing of all persons diagnosed with TB, and testing all 
HIV-infected persons for evidence of Mtb infection. In this study,out of 172 respondents 
only 120 provided HIV statsus and it was found that HIV infection was not associated 
with MDR-TB infection. This could be attributed to the fact that most of the Control 
respondents were from the different towns of Leyte (Eastern Visayas) which is not listed 
as one of the Philippines Department of Health (PDOH) HIV testing priority areas. The 
respondents in the Cases reside from the different parts of Metropolitan Manila which are 
a PDOH priority area for HIV testing besides being infected with MDR-TB (a high 
priority itself). The Updated 2010-2016 Philippine Plan of Action to Control 
Tuberculosis recommended strengthening the HIV diagnosis among TB patient even if 
the death rate is not high in TB-HIV target areas (Philippine Department of Health -
National TB Control Program, 2014). HIV testing among TB patient is not a requirement 
for all TB patients. This is consistent with the WHO Western Pacific Region data (Figure 
9); wherein in 2014 out of 250,000 newly registered TB cases only 50,000 were tested for 
HIV despite being one of the fastest-growing HIV epidemics in the world (World Health 
Organization Western Pacific Region, Philippines– Country profiles on  HIV/AIDS, 
n.d.b) 
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Figure 9. HIV Testing Among Newly Registered TB Patient in the Philippines in 2013 
and 2014. Adopted from: World Health Organization Western Pacific Region, 
Philippines– Country profiles on HIV/AIDS (n.d.b). 
  
The general mode of MDR-TB and Drug Susceptible TB transmission is through 
inhalation of the Mtb tubercle bacilli that is present in the microscopic droplets from an 
active TB infected person’s which are expulsed by coughing, sneezing, speaking, singing, 
or laughing (Versaalovic et al., 2011;National Institute of Allergy and Infectious 
Diseases,2010). Analysis of the data obtained from this study, found that self-reported 
exposure to drug-susceptible TB/MDR-TB patient was not a risk factor for MDR-TB 
infection (p = 0.07); however out of the 172 respondents, only 102 answered the question 
on exposure to drug-susceptible TB/MDR-TB patient. Results of the Chi-square test 
revealed no statistical difference (p = 0.95) between those respondents in the Cases and 
Controls that provided answers to the questions relative to exposure to drug-susceptible 
TB/MDR-TB patient. Conversely, following the scientific evidence of TB diseases 
transmission, it is clear that exposure to drug-susceptible TB/MDR-TB is a risk factor. 
This was found out in a study conducted in Kazakhstan where most study respondents 
with MDR-TB infection had previous contact with the patient with drug-susceptible TB 
or MDR-TB (Terlikbayeva et al., 2012). 
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In the Philippines diagnosis and treatment of TB is provided free by the 
government through various government hospitals and municipal health centers. It was 
found out in this study that though delayed diagnosis and treatment (from the onset of TB 
symptoms) is not associated with MDR-TB infection; 38.78% of the respondents sought 
medical help after more than one month of experiencing the signs and symptoms of the 
disease.  The primary reason patients shared is financial constraint for one has to spend 
for the transportation in going to health centers.  Most of the study respondents from the 
Controls reside in far flung areas of the town where the Municipal Health care provider is 
stationed. Going to the clinic requires a tremendous task of sacrifice especially if the area 
(Barrio) that the patient live does not have an accessible road. Some patients told the 
researcher that they would rather spend their money to buy rice (a basic staple food in the 
Philippines) rather than to pay for the transportation for in this manner more family 
member will benefit.  Delay to a timely care seeking was attributed to stigma to the 
diseases, lack of proximity to health centers and treatment partners and the perceived 
high cost of TB treatment (Philippine Department of Health -National TB Control 
Program, 2014). 
The predisposition of an infectious communicable disease should not only be 
evaluated and assessed from a biological perspective but equally important is from the 
various socio cultural, economic, behavioral factors that may have triggered an increase 
in disease susceptibility (Berkman, L. F. & Kawachi, I., 2005). Smoking, imprisonment, 
compliance with drug susceptible TB treatment regimen, alcohol use, and employment 
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status were among the various socio cultural, economic, behavioral factors considered in 
this study.  
Smoking harms nearly every organ of the body thereby diminished the overall 
health condition of the person (Butov et al, 2015). In this study, smoking was associated 
with MDR-TB infection (p = 0.04).  The researcher noted a low turnout response, 
wherein only 65 out of 172 respondents provided an answer to the smoking questions. 
The Chi-square test showed no statistical difference (p = 0.45) between those respondents 
in the Cases and Controls that provided an answer to the question relative to smoking. It 
can also be inferred from the data in the study that smoking is a generic risk factor for 
lung disease (i.e. Drug Susceptible TB, MDR-TB). The association of smoking as a risk 
factor to lung disease is scientifically explained in a study performed in Kharkiv region of 
Ukraine by Butov, Kuzhko, Makeeva, and Butova, (2015). They found out that smoking 
leads to mutation of the PM-T-330 gene IL-2 heterozygous type gene that produces white 
blood cells which are part of the body’s natural response to microbial infection. 
Besides smoking, compliance with drug susceptible TB treatment regimen was 
also found to be associated with MRD-TB infection (p = 0.001). Chi-square test showed 
that there is a high statistically significant difference (p = 0.001) found between Cases 
and Control respondents that provided an answer relative to compliance with drug 
susceptible TB treatment regimen. Despite the implementation of DOTS program by the 
Philippines Department of Health, per the treatment outcome of 2011 new smear positive 
cohort the default rate is 4% (Philippines Department of Health -National TB Control 
Program, 2014). In a study by Smith, Wolff & Nguyen (2013) and Georghiou et al. 
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(2012); noncompliance to the required TB treatment regimen such as repeated and 
inappropriate use of antibiotic is a major cause of Mtb chromosomal mutation, which 
then acquires antibiotic resistance specifically to the first line of drug treatment against 
TB. Chromosomal mutation through horizontal gene transfer alters the original genetic 
code due to repeated and inappropriate use of antibiotic (Smith, Wolff, & Nguyen, 2013). 
The use and misuse of antibiotic in which case not following the prescribe TB treatment 
regimen accelerate the emergence of drug resistant organism strain (WHO, 2015b). 
Microorganism resistance to antibiotic is a threat to public health. Daniela and Osmand 
(2011), and Skrahina et. al., (2013) identified in their respective study that history of 
previous anti-TB treatment is a risk factor for MDR-TB infection. In the Philippines 
despite the best effort of the Philippine Department of Health to provide free health care 
services to TB patients and the general population; difficulty in accessing the health care 
facilities is one of the primary reasons for not following the prescribed treatment. Most of 
the respondents live in remote areas that going to the town health centers is a big 
financial and physical sacrifice. Some patients will have to walk miles or ride on a non-
motorize boat to reach the town health center. Among the reasons cited by the 
respondents for not following the TB treatment regimen is the unavailability of the 
medicine every time they went to health centers. This is confirmed in the report of the 
Philippines Department of Health -National TB Control Program (2014) wherein 
medicine procurement challenges are encountered among which are: non-availability of a 
source for Streptomycin and medicine requested shelf life of 18 months is too short for 
the manufacturer to provide to the National Tuberculosis Control Program.  The reasons 
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cited by the respondents for not following the TB treatment regimen are: feeling better in 
the middle of the treatment period, forgetfulness, and side effects of the medicine. The 
stated reasons are not just confined to the Philippines. Economic barrier and easy access 
to health which is affected by social and political factors are some of the commonly given 
reasons why TB globally are still either not diagnosed, or their cases are not reported and 
can also have a negative impact on treatment adherence (WHO,2015a). 
Limitations of the Study 
Understanding MDR-TB infection risk factors is very critical in epidemic 
prevention. The increase in the prevalence rate of MDR-TB infection is of great concern 
among public health practitioners (Zignol et al., 2012). This study was able to established 
that in as far as the geographical area in the Philippines where the study was conducted; 
smoking is a risk factor for MDR-TB infection which is similar to the study conducted by 
Skrahina et al., (2013) in Belarus and Pant et al., (2009) done in a DOTS-Plus clinic at 
Bhim Hospital, Bhairahawa . In addition, this study also found out that non-compliance 
to drug susceptible TB treatment regimen is likewise a risk factors to MDR-TB infection. 
The finding is a kin to findings of the study conducted by Terlikbayeva et al., (2012) in 
Kazakhstan and in China by Chen et al., (2013). Smith, Wolff & Nguyen (2013) and 
Georghiou et al. (2012) in their respective study concluded that noncompliance to the 
required TB treatment regimen such as repeated and inappropriate use of antibiotic is a 
major cause of Mtb chromosomal mutation.  
This research study was able to bring-in together the research constructs in order 
to understand the possible risk factors of MDR-TB infection in the Philippines. Once the 
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researcher completed this study there were several aspects that were manifested which 
forms the limitations to this study and includes the following:  
1.  The study population is not a representative of the population in the Philippines  
 with Drug Susceptible TB and MDR-TB infection; thus results cannot be extrapolated to   
the general Philippine population. Participants of this study were from limited geographic 
areas which are the town health centers located in Leyte, San Mateo Rizal and patients 
from the PMDT section of San Lazaro Hospital. The limited geographic study area where 
the study population was recruited poses a threat to the external validity which limits the 
generalizability of the study results (Creswell, 2009; Babbie, 2007). Therefore, the risk 
factors associated to MDR-TB infection that was identified in this study could not be 
applied in some parts of the country.  
2.          Limited time, and logistical challenges when working without supporting 
resources      (Supplemental staff from within the PDOH).  Supporting resource through 
the use of PDOH staff from the different area of the country could have expanded the 
geographic area of the study and allow more respondents to participate in the survey. 
Confirmation of this research should plan for an expanded set of support resources to 
enable a representative study to be conducted. 
3.         The questionnaire was not piloted and evaluated within the target population. 
Questionnaire pilot study followed by evaluation is very critical to discover the  
discrepancy and is very important in the standardization of the study instrument 
(Nachmias and Nachmias, 2008). 
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4.         Not all the 172 respondents provided answer to all items in the questionnaire 
which may have biased the statistical test results. Further, the number of MDR-TB and 
Drug Susceptible TB respondents were not equal. An equal number of respondents could 
present a more careful interpretation existing between the variable (Babbie, 2007).  
5.       The data in the study was obtained through questionnaire that is written in Pilipino 
which is the national language of the country. This may have limited the number of 
respondents since even with free elementary education some potential study respondents 
cannot read and understand Pilipino thus were not able to be part of the study. 
Understanding the question is very important in survey research in order to provide 
accurate retrospective data. The questionnaire could have been written in the   
respondent’s dialect so that it is easier and friendlier to the respondents, and could 
provide a more accurate answer. 
6.  Multivariate regression analysis could was not performed because of the limited 
sample size in the study. 
 
Recommendations 
The primordial reason why the study was approve by the Philippine Department 
of Health specifically the National Tuberculosis Control Program was that the topic was 
in the research agenda of the TB program. Though the conclusion of the study cannot be 
generally applied in the country because of the limited number of respondents and 
geographical area covered, however the results of the study can provide baseline 
information in case a similar nationwide study is conducted by the Philippine Department 
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of Health.  Based on the result of the data analysis gathered from this study, the following 
are the suggested refinements in order to increase enrollment to the study which will 
minimize unanswered questions and prevent the increase of MDR-TB infection in the 
country.  
1.  Standardize the questionnaire so that the measuring instrument is most appropriate and 
therefore measures what the study intend to know. In the original proposal, this was 
part of Phase 1, however, due to the interest of time and geographical location of the 
study area this was not pursued.  
2.   The questionnaire should be written in various dialects spoken by the respondents in 
the area.  
3.   Obtain assistance from the staff of the health clinic to accommodate large number 
respondents. Though it has to be noted that the original proposal called for this, but 
the IRB insisted that the investigator not to utilize support staff in data collection. 
4.   Data should be collected following a face-to-face interview using the structured  
     questionnaire instead of traditional paper and pencil self-administration.  
5.   Request assistance from the PDOH staff to facilitate medical record reviews, help 
with data collection/survey administration/data computerization) to enable inclusion 
of a much larger representative sample of Pilipino with TB/MDR-TB cases from 
around  the Philippines. 
6.   Execute a pilot study to evaluate and assess that the aforementioned suggested 
refinements have improved the response rate, the completion rate, and reduced 
significantly the amount of missing information (unanswered questions).  
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7.   HIV testing to TB patient in the Philippines is required among patient above 15 years 
old, living in pre-identified priority areas and belong to high risk group (Philippines 
Department of Health-National TB Control Program, 2014). The aforementioned 
PDOH policy is not aligned with the WHO guidelines regarding routine HIV testing 
of all persons diagnosed with TB, and testing all HIV-infected persons for evidence 
of Mtb infection. I recommend revising current PDOH policy on HIV testing to 
completely follow the WHO recommendation to prevent premature death of HIV 
infected person from dying of TB,   and avert the dissemination of TB (especially 
MDR-TB) in the process. 
8.   It was found out in this study that one of the reasons cited by the respondents for not 
following the TB treatment regimen is the unavailability of the medicine every time 
they went to health centers. This is confirmed in the report of the Philippines 
Department of Health -National TB Control Program (2014) wherein medicine 
procurement challenges are encountered. The researcher propose that there should be 
a regular supply of anti TB medicine to various towns’ health centers to make certain 
that DOTS is strictly implemented. 
9.   Evaluate current system of anti TB medicine delivery to health centers to ensure 
sustainable supply and ultimately improve patient compliance to treatment. 
Implication for Social Change 
Tuberculosis is the leading cause of morbidity and mortality in the Philippines 
Vianzon, Garfin, Lagos, and Belena (2013). On the global scale, the country is the ninth 
out of the 22 highest TB-burden countries and has one of the highest burdens of MDR-
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TB (WHO, 2014a). The emergence of MDR-TB poses a serious threat to TB control in 
developing countries; besides being difficult and expensive to treat, the disease requires a 
longer period of treatment.  WHO interactive database on the treatment outcomes of 
MDR-TB cases in the Philippines showed that only 42% of the reported MDR-TB cases 
in 2010 were successfully treated, 14% died, 2% failed treatment, 36% were lost to 
follow-up, and 7% were not evaluated (WHO, 2014a).  
There is no study in the Philippines on the risk factors of MDR-TB. The 
Philippine Department of Health through the National Tuberculosis Control Program 
agreed to approve the conduct of the study since the topic is on the research agenda of the 
TB program. This study can help inform the planning of future nationwide MDR-TB 
research through the lessons learned as discuss in the recommendation section of this 
chapter.  
The findings could contribute to positive social change in that they will provide 
information to individual, TB Control program Director, and health care providers that 
could help develop programs for drug susceptible TB to stop smoking and comply with 
the anti TB drug treatment regimen to prevent MDR-TB infection. Further, the result of 
the study can promote positive social change in that knowing the risk factor can provide 
guidance to health workers in the identification of high-risk patients for MDR-TB 
infection. The recognition of potential MDR-TB infected patient may help improve TB 
case findings considering that the patient could potentially infect immediate members of 
the family or person that he/she was in contact and which may result in increase of the 
current national TB smear-positivity rate. Understanding the risk factors related to the 
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onset of a disease is very critical in epidemic prevention. The persistent increase in the 
prevalence rate of TB specifically MDR-TB (Zignol et al., 2012) continued to raise 
concern among public health practitioners. The result of the study can guide in the early 
identification of MDR-TB infection and treatment which will minimize the detrimental 
biological, psychological and social effects of the disease. 
Another positive social change in the study was that the researcher was able to interact 
various TB Health Care Providers especially the personnel in the National Tuberculosis 
Control Program of the Department of Health, Member of the Ethics Committee of San 
Lazaro Hospital, PMDT Center of San Lazaro Hospital and Staff of the different Towns 
Health Care Centers. The study provided an opportunity for the researcher to interact 
with the different TB patients who were very candid and friendly in sharing their 
thoughts about their current health conditions. 
Conclusion 
The primary goal of public health practitioner is to prevent the proliferation of 
MDR-TB in the community. One method that is employed is through case finding using 
risk factor. As such appreciating, the risk factors related to human infection of MDR-TB 
is critical in case finding.  Understanding the potential risk factor associated to MDR-TB 
was consistent with the epidemiological theory of John Snow that was applied in this 
study. He theorized that the cause of communicable disease can be determined using a 
case-control study design to assess associations between potential risk factors 
(independent variables) and the outcome (MDR-TB, the dependent variable) (Frerichs, 
2009).  
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Multidrug-resistant Mycobacterium tuberculosis accounts for 4.0% of all new 
cases of TB in the Philippines (WHO, 2013a). Despite such high percentage rate of 
MDR-TB infection in the Philippines, there is no study done that determine the possible 
risk factors that contribute to the continued increase of MDR-TB infection in the country. 
It is for this reason that the Philippine Department of Health through the National 
Tuberculosis Control Program approved that the study be conducted for the subject of the 
study is part of the NTP research agenda as well.  
This research investigated the possible risk factors that are associated with MDR-
TB infection. The risk factors that were considered are: (a) previous TB treatment, (b) 
infection with Human Immunodeficiency Virus, (c) exposure to TB patient, (d) delayed 
TB diagnosis and treatment, (e) smoking, (f) imprisonment,  (g) compliance with the TB 
treatment regimen,( h) alcohol abuse, and (i)employment status.  
Results were used to answer the research questions which established that drug 
susceptible TB who smoke on a daily basis are three times likely to develop MDRT TB 
infection. Further, data in this study indicated that drug susceptible TB patient is nine 
times more likely to develop a MDR-TB infection if the anti TB treatment regimen is not 
complied.  
There are some limitations to this study that need to be taken into consideration 
and that could contribute further to literature. Among the limitations was the 
geographical location of the study area which limits the generalizability of the study 
results. Another important limitation was to standardize the questionnaire, translate the 
questions into various dialects, administer through face to face interview by the staff of 
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the health clinic to accommodate large number respondents and minimize unanswered 
questions.  
The results of this study can add to the literature on MDR-TB infection in the  
Philippines and as a bench mark for further studies that will be conducted by NTP on  
the national level. The MDR-TB infection is a preventable disease. Education, health  
guidance and counselling coupled with effective treatments through strict adherence to  
DOTS are the keys to decreasing its prevalence.
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Appendix A: Request to Conduct Research 
 
 
Name of the Clinic/Hospital Administrator 
Address of the Clinic/Hospital 
 
 
Dear Sir/Madam 
 
 
This letter serves to request for your permission to conduct survey research on drug 
susceptible TB and MDR-TB patients in your clinic/hospital/organization. I am presently 
a Ph.D.in Public Health student at Walden University in the United States of America. 
The title of my study is: “Possible Risk Factors of Multi-Drug Resistant Tuberculosis 
Infection Prevention in the Philippines”. The proposed study will assess the strength of 
association between several possible risk factors and the MDR-TB infection. The 
research is done to fulfill the dissertation research requirement of the degree.  
 
Once permission is granted by your good office the following procedure will be followed. 
 
1. The researcher will provide to prospective study recruits the Study Information 
and Participation Consent (in Filipino Language) and orientation discussion 
where they are free to ask questions about the study and will be given ample time 
around an hour to decide.    
 
2. Once potential recruits volunteer consented in the study the researcher will assign 
a study ID Number which will be entered in the data base, questionnaire and 
respondent’s - clinical record extraction form. 
 
3. The questionnaire that is in Filipino language will be placed inside an envelope 
and distributed to respondents. The respondents will answer the questionnaire in 
an area designated by your facility. 
 
4. The respondents will hand over the envelope with the answered questionnaire to 
the researcher for review and storage. 
 
5.  The researcher will provide a list of patient to the clinic/hospital and the envelope 
with the respondents clinical record extraction form. 
 
6. Clinic/Hospital will be requested to review the patient clinical record to verify 
whether the patient is either a laboratory confirmed MDR-TB or a laboratory 
confirmed Drug Susceptible TB, and the most recent HIV test result (if available) 
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and will be documented in the RESPONDENT’S - CLINICAL RECORD 
EXTRACTION FORM.  
 
7. The researcher will develop a data base for analysis to answer the research 
questions.   
 
Findings of the study can be shared to interested parties such as supporting study 
participants, the supporting TB Centers, the Philippines DOH, and WHO. 
 
No clinical test will be administered to patients who volunteered to be in the study, nor 
will they be paid or receive any gifts for the participation in the study. It is hoped that the 
research findings may help prevent others from developing MDR-TB.  
 
The researcher’s Dissertation Committee and Walden University’s Institutional Review 
Board (IRB) (identified below) will assure that ethical principles are adhered to 
throughout the conduct of this research. 
 
Donald Goodwin, DrPH,  
Dissertation Committee Chair 
Email [redacted] 
 
IRB@waldenu.edu 
Walden University  
Research Participant Advocate 
 
I hope that my request shall meet your favorable consideration 
 
Yours Faithfully 
 
Molovon P. Azores Jr.  
Investigator 
Student Ph.D. Public Health 
College of Health Sciences 
Walden University 
E-mail: [redacted 
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Appendix B: Respondents Clinical Record Extraction Form 
 
Treatment Center: _______________________ 
Respondent’s Study ID No. _____________________ 
 
A. Drug Susceptibility Testing (DST) Result 
_____ No Resistance/Sensitive to Antibiotic 
_____ Resistance to Antibiotic 
 
                      M. tuberculosis/culture has been found resistance to: 
                           
                   _______ Isoniazid (INH) _______ Rifampicin (RIF) 
                  _______ Ethambutol (EMB)  _______ Pyrazinamide (PZA)  
                       _____________ Others     
  
 
B. Type of AIDS Test performed (if available): _____________ 
C. HIV test result:    
       _________Positive _____ Negative 
                           Date Tested: ___________ 
 
 Documented by: ____________________     Date: __________ 
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Appendix C: Questionnaire 
Respondent’s Study ID No. ________________ 
MDR-TB: _______          Non-MDR TB: ______ 
DEMOGRAPHIC INFORMATION 
Instruction: Please check the appropriate answer. 
1. Gender:  
             Male ___   Female: ___ No Answer: _______ 
2. Age: _____                                 
3. Place of Birth:   ____ Luzon     _____ Visayas     _____ Mindanao 
4. What is your highest level of education? 
None: _____ Elementary: _____ High school: _____ 
College: _____ Master’s: ______ Doctorate: ______ 
5. What is your employment status? 
 
Unemployed: _____ Employed: ______  
Retired: _____ 
6. What is your main source of income? 
Fishing/Farming ______   Employment income ______ 
Business enterprise ______ Property Rental _______ 
Others, please specify _______ 
 
RISK FACTORS INFORMATION 
 
A. Previous exposure to drug susceptible TB/MDR-TB patient, delayed 
diagnosis and treatment 
1. Do you know if you had been in contact or exposed to someone with TB before 
you got the disease? 
Yes ___                No __                     Don’t Know ___ 
 
2. If “No” or “Don’t Know” please skip to Q5. 
If yes where? 
Home ____  Work-place ____  Friends ____ Prison 
 ____ Others please specify_______________ 
3. How often were you in contact with someone with TB?  
                         ______ Occasionally _____ Monthly    ___less than Monthly 
 
4. How long had you been in contact with someone with TB before you were 
diagnosed with TB? 
                    Less than 2 months ______                  2 to 6 months _____  
                         More than 6 months ____  
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5. Please check the symptoms that you had been experiencing before you were 
diagnosed as having TB. 
____ Cough that lasted 3 weeks or longer              ____ Pain in the chest 
____ Coughing up blood or sputum                        ____Weakness 
____ Fatigue                                                            ____ Weight loss   
____ No appetite                                                     ____ Chills   
____ Fever                                                              _____Sweating at night  
____ Shortness of breath                          
6. Did you immediately visit a doctor or seek medical help? 
                       Yes ____                                  No _______ 
 If “No”, skip to Q8. 
 
7. If yes, How long did it take to visit a doctor?  
One week or less _____       Two weeks _____ 3 Weeks _____ 
A month _______                Greater than 1 month_______ 
I don’t remember ______ 
8. If you did not seek medical help immediately, why? 
Please state: ______________________________ 
 
B. Previous TB treatment and compliance with treatment regimen 
9. Is this your first time to have TB? 
Yes _____                    No _______ 
 
If “Yes”, skip to Section D. 
 
10. Have you previously received TB treatment? 
No ____                        Yes ______ 
If “No”, skip to Section C. 
 
11. Do you remember the drug prescribed to you? 
Yes ____                      No ____  
If “No”, skip to Q13. 
 
12. If yes please, please check the drug prescribed to you by the Doctor. 
_______ Isoniazid (INH)                       _______ Rifampicin (RIF) 
_______ Ethambutol (EMB)                 _______ Pyrazinamide (PZA) 
_________________________ Others      
13. Was your treatment supervised by Directly Observed Treatment Short (DOTS) 
course personnel? 
Yes ______                   No _______ 
14. Did you follow the prescribed treatment regimen? 
Yes _____                     No _____ 
15. Why did you not follow the prescribed treatment regimen? Please specify 
______________________________________________________________ 
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16. Did you complete the treatment? 
Yes _____   No ______ 
If no, why did you stop the treatment? Please specify 
__________________________________________________________       
 
                    
C. Human Immunodeficiency Virus  
18. Have you been tested for HIV infection? 
Yes ____   No ____ 
19. Have you been told by your doctor that you have HIV? 
Yes _____   No ___ 
20. What month and year  were you  diagnosed to have HIV _________ 
 
21.  Were you treated with HIV? ______ Yes           No_______ 
 
22.  If so please check the medicine you took for  HIV. 
 Agenerase (amprenavir)                       Combivir (AZT + 3TC)   
 Complera (Truvada + 
Edurant) 
 
Crixivan (indinavir) 
 Edurant (rilpivirine)                              Emtriva (emtricitabine) 
 Epivir (lamivudine, "3TC")  Fortovase (saquinavir)   
 
Fuzeon (enfuvirtide)    
 Hivid (zalcitabine, 
"ddC")   
 Invirase (saquinavir)  Kaletra (lopinavir) 
 Lexiva (fosamprenavir)  Norvir (ritonavir)          
 
Rescriptor (delavirdine)   
 Retrovir (zidovudine, 
"AZT")   
 
Reyataz (atazanavir)    
 Stribild (Emtriva + 
Viread + elvitegravir) 
 Sustiva (efavirenz  Tivicay (dolutegravir)    
 Triumeg (dolutegravir + 
abacavir + lamivudine) 
 Trizivir 
(AZT/3TC/abacavir) 
 Truvada (Emtriva + Viread)  Tybost (cobicistat) 
 Videx (didanosine, "ddI")  Viracept (nelfinavir) 
 Viramune (nevirapine)  Viread (tenofovir)                             
 Vitekta (elvitegravir)  Zerit (stavudine, "d4T") 
 
Ziagen (abacavir) 
others 
(please 
specify) 
 
 
D. Imprisonment 
 
23. Have you been in prison?      
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Yes _____     No _____ 
24. If yes, what year you went out of prison? _____ 
 
E. Smoking 
 
25. Have you ever smoked cigarettes?  
Yes ____    No _____ 
26. At what age did you start smoking cigarettes? ___________ 
27. Do you still smoke cigarettes at present? 
Yes _____    No _____ 
28. Do you smoke cigarettes daily or occasionally? 
Daily ______     Occasionally ____ 
29. How many cigarettes do you consume? 
Less than 1 pack a week ________                 1 pack a week ______ 
2 to 3 pack a week ______                              More than 3 pack a week ______    
Don’t know occasional only _____ 
30. Did you stop smoking? ________ 
31. At what age did you stop smoking? _______ 
 
F. Alcohol Consumption 
 
32. Do you drink alcohol? 
Yes ____    No _____ 
33. What type of alcoholic drink do you usually take? 
Beer ______    Wine _____   Liquor/Spirit _____ 
Locally made alcohol drink (i.e. tuba, lambanog) ______ 
34. How often did you drink beer, wine, liquor/spirit or any locally made alcoholic  
      drink (i.e. tuba, lambanog)? 
             
            Every day ____     Once a week _____ Occasional only ______ 
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Appendix D: Translation Validation Form for Study Information and Consent Form  
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Appendix E: Study Questionnaire Translated into Tagalog 
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Appendix F: Permission to Conduct the Study from the Philippines Department of Health 
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Appendix G: Approval to Conduct the Study from Burauen, Leyte Health Center  
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Appendix H: Approval to Conduct the Study from Tanauan, Leyte Health Center 
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Appendix I: Approval to Conduct the Study from Capoocan, Leyte Health Center  
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Appendix J; Approval to Conduct the Study from Barugo, Leyte Health Center  
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Appendix K; Approval to Conduct the Study from Dagami, Leyte Health Center  
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Appendix L; Approval to Conduct the Study from Carigara, Leyte Health Center 
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Appendix M; Approval to Conduct the Study from San Mateo, Rizal Health Center  
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Appendix N: Approval to Conduct the Study from San Lazaro Hospital  
 
